

TABLE OF CONTENTS

	<u>PAGE</u>
I. INTRODUCTION	1
II. JURISDICTION AND VENUE	8
III. PARTIES	9
IV. STATEMENT OF FACTS	13
A. Drug Manufacturers and NDCs	14
B. The Wholesale Acquisition Cost	15
C. The Average Sales Price	16
D. The Average Wholesale Price.....	16
E. The WAC-to-AWP Spread	17
F. Drug Wholesalers.....	18
G. Wholesaler Sales Transactions	19
H. Retail Pharmacy Channel.....	20
I. The Private End Payors for Prescription Drugs.....	21
J. End Payors Drug Reimbursements are AWP-Based	22
K. Medicaid Drug Reimbursements are AWP-Based as are Connecticut’s Payment	23
L. Medicare Drug Reimbursements are AWP-Based	25
M. PBMs.....	27
N. U&C Payors	28
O. The Brand Drug Pharmaceutical Market was Conducive to a Price Fixing Scheme	28
P. Private and Public End Payors Rely on Published Drug Pricing Compendia.....	29
Q. The Emergence of First Data and MediSpan as Electronic Data Publishers	30
R. The Merger of First Data and MediSpan Systems.....	33
S. First Data Gains the Trust of the Pharmaceutical Industry.....	35

T. First Data’s Representations to Gain Marketplace Reliance on Its Pricing Data37

U. In the Late 1990s, Retailers Looked to the WAC/AWP Spread to Increase Margin39

V. By 2001, First Data WAC-to-AWP Markups Were Susceptible to Abuse41

W. Implementation of the Five Percent Spread Scheme43

X. McKesson’s Purpose in Implementing the Scheme was to Curry Favor With Retailers and Gain a Competitive Advantage Over Other Wholesalers.....55

Y. McKesson/First Data Collaborate to Hide the Scheme55

Z. Some Branded Manufacturers’ Response to the McKesson/First Data Scheme59

AA. First Data’s March 2005 Announcement.....60

BB. Fraudulent Concealment.....61

V. CLAIMS FOR RELIEF63

FIRST COUNT CIVIL RICO (18 U.S.C. § 1962(C)).....63

A. The McKesson-First Data Enterprise.....64

B. The Defendant’s Use of the U.S. Mails and Interstate Wire Facilities.....69

C. Conduct of the RICO Enterprises’ Affairs.....71

D. The Pattern of Racketeering Activity72

E. The State Relied on the Accuracy of the Falsely Inflated AWP’s Published by First Data and/or MediSpan.....73

F. Damages Caused by McKesson’s Five Percent Spread Scheme74

SECOND COUNT SECTION 1 OF THE SHERMAN ACT (15 U.S.C. § 1).....75

THIRD COUNT USE OF DECEPTIVE TRADE PRACTICES IN VIOLATION OF THE CONNECTICUT UNFAIR TRADE PRACTICES ACT (CONN. GEN. STAT. § 42-110A, *et seq.*)78

FOURTH COUNT WILLFUL USE OF DECEPTIVE TRADE PRACTICES IN VIOLATION OF CONNECTICUT UNFAIR TRADE PRACTICES ACT (CONN. GEN. STAT. § 42-110A, *et seq.*).....79

FIFTH COUNT USE OF UNFAIR TRADE PRACTICES IN VIOLATION OF CONNECTICUT UNFAIR TRADE PRACTICES ACT (CONN. GEN. STAT. § 42-110A, *et seq.*)80

SIXTH COUNT WILLFUL USE OF UNFAIR TRADE PRACTICES IN VIOLATION
OF CONNECTICUT UNFAIR TRADE PRACTICES ACT (CONN.
GEN. STAT. § 42-110A, *et seq.*)81

PRAYER FOR RELIEF81

I. INTRODUCTION

1. The State of Connecticut (“Plaintiff” or “the State”), represented by Richard Blumenthal, Attorney General of the State of Connecticut, acting at the request of Jerry Farrell, Jr., Commissioner of Consumer Protection, brings this action pursuant to the Connecticut Unfair Trade Practices Act (“CUTPA”), Chapter 735a of the Connecticut General Statutes, and more particularly, Conn. Gen. Stat. §§ 42-110m and 42-110o, for the purposes of seeking appropriate relief for violations of Conn. Gen. Stat. § 42-110b(a). The State seeks, pursuant to CUTPA, to obtain restitution, civil penalties under the applicable laws, and injunctive and other equitable relief against Defendant McKesson Corporation (“McKesson”) for payments made for prescriptions of brand-name drugs covered by the State of Connecticut’s publicly funded health programs, as well as for consumers, who were injured as a result of the deceptive practices McKesson caused to be injected into the pricing of brand-name drugs.

2. The State of Connecticut similarly brings this action pursuant to the federal Racketeering Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. §§ 1961 and 1962. McKesson and its officers or employees associated itself with First DataBank, Inc. and its officers or employees to form a RICO association-in-fact and engage in a pattern of Racketeering activity including multiple episodes of mail and wire fraud, all designed to increase the AWP for brand-name drugs. McKesson and its co-conspirators engaged in numerous overt and predicate fraudulent racketeering acts in furtherance of the conspiracy to violate RICO. The State and consumers were injured in their property as a result of the deceptive practices undertaken by the RICO associations-in-fact and seek to obtain treble damages and other injunctive and equitable relief against McKesson for payments made for prescriptions of brand-name drugs.

3. The State of Connecticut further brings this action pursuant to 15 U.S.C. § 15 for violations of 15 U.S.C. § 1. The combination or conspiracy alleged in this Complaint consists of

a continuing agreement, understanding or concert of action by McKesson, along with its co-conspirator, First DataBank, the substantial terms of which were to raise, fix and maintain the AWP's of brand-name drugs at 25% over WAC, and raised prices in the market for brand-name drugs. The effected market is the market for brand-name drugs.

4. The State of Connecticut, through the Connecticut Department of Social Services ("DSS"), administers the Connecticut Medical Assistance Program ("CMAP"). The CMAP includes the Connecticut Medicaid program, as well as the Connecticut Pharmaceutical Assistance Contract to the Elderly and the Disabled ("ConnPACE"), State Administered General Assistance ("SAGA"), Connecticut AIDS Drug Assistance Program ("CADAP") and Healthcare for Uninsured Kids and Yout ("HUSKY"). The CMAP pays for medical benefits, including prescription drugs for certain low-income and disabled Connecticut residents and reimburses physicians, pharmacists, and other health care providers for certain drugs, diagnostic procedures and/or other health care services prescribed for, dispensed, and/or administered to CMAP recipients. Similarly, many Connecticut consumers pay all or part of the cost of brand-name drugs.

5. McKesson's deceptive practices and unlawful acts involved a scheme and course of conduct that directly resulted in the transmission and publication of false and misleading information concerning AWP's. These deceptions resulted in injuries to the state program including CMAP. The CMAP was and will continue to be forced to bear millions of dollars of excess charges arising from the scheme and the fraudulent AWP's.

6. The exact identity of the drugs covered by this lawsuit is capable of being discovered from the records of First DataBank. Based on an investigation of First DataBank's databases, the list of such drugs is attached as Exhibit A ("Marked Up Drugs").

7. In the pharmaceutical marketplace, those in the retail distribution chain – national chain drug pharmacies, independent pharmacies, mail order houses and other retailers – purchase drugs on the basis of the published wholesale acquisition cost or “WAC,” a benchmark price established by manufacturers and used by them and wholesalers to establish prices to retailers. Although retailers *buy* pharmaceuticals on the basis of WAC, they *get paid* (*i.e.*, get reimbursed) for branded drugs based on a different benchmark, *the average wholesale price or “AWP.”* As the difference between AWP and WAC increases, the larger “spread” affords retailers and other middlemen like pharmaceutical benefit managers (“PBMs”) opportunities for larger profits.

8. Each year more than three billion prescriptions are written in the United States. The various actors in the marketplace must have a way of determining what the AWP is at any moment in time for the approximate 65,000 drugs used in the marketplace. AWP’s are, therefore, compiled and published by publishing companies, including First DataBank (“FDB” or “First Data”) and Medispan. Through these compilations, which are available in both hard copy and electronic form, those in the distribution chain can determine the AWP for any given drug and effectuate reimbursement accordingly.

9. Consumers, health and welfare plans, health insurers and governmental entities, including the State’s Medicaid program and other governmental entities, (“Payors”) pay for prescription drugs use and rely on AWP in doing so. Virtually all these entities had contracts for the brand-name drugs at issue that use AWP as a pricing standard.

10. First Data, McKesson and pharmaceutical companies know that governmental and public payors, such as CMAP and other State programs, utilize AWP as a pricing benchmark.

11. Until March 15, 2005, First Data represented to those in the pharmaceutical market that it derived the WAC/AWP markup either from manufacturers or by conducting “a


survey” of wholesalers whose purpose was to verify prices reported by the manufacturer. First Data further represented that AWP represents the “average of prices charged by the national drug wholesalers,” and that the number of surveys it was conducting to determine the published AWP was “increasing.” McKesson is one of the wholesalers who was purportedly “surveyed” by First Data as part of this process.

12. Historically, in order to arrive at the AWP for branded drugs, manufacturers and/or wholesalers applied a markup of 20% or 25% to WAC. Whatever markup was given to a particular branded drug “stuck” with that drug indefinitely. Until 2002, there was variation, supposedly based on manufacturer direction or on First Data’s wholesale surveys, in the difference between the WAC to AWP spread for hundreds of brand-name drugs. For example, manufacturer A might have a markup of 20%, while manufacturer B might utilize a markup of 25%.

13. In late 2001, First Data and McKesson reached a secret agreement on how the WAC to AWP markup would be established for hundreds of brand-name drugs. The two companies agreed to artificially raise and fix the price on brand-name drugs and therefore artificially raise prices in that market. As part of this agreement, First Data, to the extent it received information from others besides McKesson, used the WAC-to-AWP markup provided only by McKesson as the basis for its published AWP and did not “survey” any other wholesalers. To the extent FDB did receive material from other wholesalers, such material was not the basis for the FDB published AWP, only McKesson’s information was. McKesson knew that FDB was using its pricing as the basis for setting the markup over WAC. Sometimes, within a day or less of requesting a price change or markup from McKesson, FDB responded by increasing the markup.

14. As part of their agreement and conspiracy, McKesson and First Data, without any legitimate economic justification and without any pro-competitive effect, raised the WAC-to-AWP spread to 25% for over four hundred brand-name drugs that previously had received only the 20% markup amount. To conceal the scheme, McKesson and First Data agreed to typically effectuate price changes only when some other WAC-based price announcement was made by a drug manufacturer. This camouflaged both the associated increase in the WAC-to-AWP markup and WAC-to-AWP spread and McKesson as the source of the increased markup. McKesson communicated these new WAC-to-AWP spreads to First Data. First Data, without regard to any change in the actual average wholesale prices occurring in the pharmaceutical marketplace, and without reference to the manufacturers' suggested AWP (or WACs) for these drugs, and without surveying other wholesalers, then published new AWP with the new WAC-to-AWP markup. First Data did so despite receipt of information, in some instances, directly from manufacturers specifying or suggesting a 20% markup as appropriate. On some occasions, some of the manufacturers secretly questioned this increase, but First Data refused to change the published AWP and the manufacturers failed to take any action to remedy First Data's unjustified raise in AWP.

15. This secret plan and collaboration between McKesson and First Data to raise the WAC-to-AWP spreads is referred to as the "Five Percent Spread Scheme" or "Spread Scheme" or "Price Fix." The dramatic nature of the Spread Scheme is illustrated by the following chart depicting the hundreds of drugs whose WAC-to-AWP spread was raised as part of the Spread Scheme. The spike in 2002 reflects implementation of the Spread Scheme:



Note: “NDC” means National Drug Code and refers to a number assigned to each drug.

16. Once McKesson and First Data raised the WAC-to-AWP spread to 25% on a given drug, that spread remained in place and still remains in place to this day and thus continues to injure those entities – including the State – that rely on AWP as a pricing standard.

17. McKesson had an economic incentive for implementing the scheme. A major part of McKesson’s business comes from large pharmaceutical retail chains and other retail pharmaceutical clients. McKesson implemented this scheme in order to provide a benefit to those important retail pharmacy clients. Pharmacies are reimbursed by health plans, CMAP and other State programs, based on AWP. Consequently, pharmacies make a profit on the spread between AWP and their acquisition cost for a drug. Under this system, a higher WAC-to-AWP spread results in increased profits to pharmacies. Thus, an increase in the WAC-to-AWP markup results in larger profits for retailers.

18. McKesson was proud of its efforts and quietly and secretly boasted to select retail clients that McKesson “had been working on AWP expansion with some success.” Internally McKesson noted that clients were “very glad that McKesson was doing this.” MCKAWP 0069726. Confirming the secrecy of the scheme, McKesson cautioned that its “AWP expansion effort” and information about McKesson’s role in inflating AWP is “not intended to be handed out to customers” but could be described to show “McKesson is doing our part.” MCKAWP 0069732. “AWP expansion” was a McKesson euphemism for the WAC-to-AWP price fix.

19. First Data agreed to this scheme to ease the burden of having to establish accurate spreads and to maintain the demand for its business among entities in the pharmaceutical distribution chain whose reimbursement is based on AWP, even though First Data knew that it no longer had the industry contacts and cooperation necessary to ensure the publication of accurate pricing. Thus, First Data and McKesson shared multiple common purposes, though they may have had different reasons for doing so, and each acted to achieve those purposes by implementation of the 5% Scheme.

20. The State has contracts that tie its payments for pharmaceuticals to First Data’s or Medispan’s published AWP. Medispan’s AWP were derived directly from FDBs.

21. As a result of this artificial increase in the markup of the WAC-to-AWP spread from 20% to 25%, the State has had its drug prices increased by the scheme.

22. Among the drugs whose prices are artificially inflated by the scheme are some of the top brand-name drugs used by hundreds of millions of Americans, such as: Allegra (a leading allergy drug), Azmacort (a leading asthma drug), Celebrex (a leading arthritis/pain medicine), Coumadin (a leading anticoagulant), Flonase (a leading asthma drug), Lipitor (the world’s top selling drug, a statin), Neurontin (a leading pain medication), Nexium (a leading

reflux drug), Prevacid (a leading ulcer/reflux drug) and Valium. Given the billions of dollars spent on prescription drugs, a 5% increase in the WAC-to-AWP spread results in a substantial increase in payments for pharmaceuticals. For example, AstraZeneca's Nexium had annual sales in 2004 of almost \$4 billion. A bump of 5% in the WAC-to-AWP spread results in an increase of over \$100 million per year in reimbursements for just one drug. Another such drug is Pfizer's Lipitor, whose annual sales in 2004 exceeded \$10 billion. As a result of the 5% increase imposed by First Data and McKesson, hundreds of millions per year was spent on Lipitor that would not have been absent the scheme.

23. In this action, the Plaintiff State of Connecticut seeks to recover damages incurred and/or restitution resulting from McKesson's unlawful acts and practices, as well as appropriate equitable and/or injunctive relief, civil penalties, costs of litigation including attorneys' fees, and all other relief authorized by law. It asserts claims for violations of RICO, 18 U.S.C. § 1962(c), the Sherman Act § 1, 15 U.S.C. § 1, and the Connecticut Unfair Trade Practices Act, CONN. GEN. STAT. § 42-110a, *et seq.*

24. McKesson knew that the CMAP would be injured to the extent it was forced to provide, pay and/or reimburse for prescription drug expenditures at inflated prices. The State seeks restitution to CMAP for the added expenses incurred in purchasing or reimbursing for prescriptions as a result of the scheme, as well as civil penalties for each violation.

II. JURISDICTION AND VENUE

25. Subject-matter jurisdiction is proper in this Court pursuant to 28 U.S.C. § 1331 because Plaintiff asserts federal causes of action and pursuant to 28 U.S.C. § 1337 since an antitrust claim is asserted, and 18 U.S.C. § 1964 because a violation of the RICO statute is asserted.

26. Subject matter over the state law claims is proper in this Court pursuant to 28 U.S.C. § 1367(a) because such claim is so related to claims in this action within the Court's original jurisdiction that it forms part of the same case or controversy under Article III of the United States Constitution.

27. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391(a) and (c) because defendant as a corporation is "deemed to reside in any judicial district in which [it is] subject to personal jurisdiction" and because the misrepresentation and material omissions "giving rise to claim[s] occurred" in this District as well as throughout the Commonwealth of Massachusetts. Venue is also proper in this District pursuant to RICO's special venue provision, 18 U.S.C. § 1965, and the Clayton Act § 12, 15 U.S.C. § 22 because McKesson transacts business throughout the State of Massachusetts. Further, this District is also the location of cases asserting similar claims against McKesson. *See New England Carpenters Health Benefits Fund v. First Databank, Inc. and McKesson Corporation*, Civil Action No. 05-11148-PBS (D. Mass.).

III. PARTIES

28. The State of Connecticut brings Counts 3-6 of this action in its sovereign capacity, brings Counts 1 and 2 of this action in its proprietary capacity.

29. The State of Connecticut, through the Department of Social Services ("DSS") administers the Connecticut Medical Assistance Program ("CMAP"). The CMAP includes the Connecticut Medicaid program, as well as the Connecticut Pharmaceutical Assistance Contract to the Elderly and the Disabled ("ConnPACE"), State Administered General Assistance ("SAGA"), General Assistance ("GA") and Connecticut AIDS Drug Assistance Program ("CADAP") and Healthcare for Uninsured Kids and Youth ("HUSKY").

30. Through these programs, the State pays all or part of enrollee's medical benefits, including prescription drugs, for families with children under the age of 21, pregnant women and

newborns, adults without children, adults with disabilities, people age 65 and older, and people living in nursing homes. Much of the budget of the DSS, which is comprised of federal, state and local funds, is devoted to these health care programs. The CMAP pays for medical benefits, including prescription drugs and reimburses physicians, pharmacists, and other health care providers for certain drugs prescribed for, dispensed, and/or administered to, Medical Assistance recipients.

31. The ConnPACE program aids the elderly and disabled with prescription expenses.

32. The SAGA program provides financial and medical assistance to indigent Connecticut residents and families who do not qualify for Medicaid.

33. The CADAP program pays for select drugs that may prevent further deterioration of the health of persons with HIV or AIDS.

34. The HUSKY program provides prescription drugs and other health benefits to children and eligible caregivers in Connecticut. Benefits are offered on a sliding scale, depending upon family income. HUSKY currently covers more than 230,000 children and teens in Connecticut.

35. The State of Connecticut provides prescription drug and/or health care benefits to certain of its residents through a variety of additional programs or departments, including the State's community health centers, public hospitals and Department of Corrections.

36. In addition to these wholly state-funded programs, the State of Connecticut also provides a Medicaid program. Under the federal Medicaid statutory scheme, states are entitled to federal financial participation to reimburse a portion of the amount the state pays pharmacies for covered outpatient drugs. 42 U.S.C. § 1396r-8. The Connecticut Medicaid program works to ensure low income families with dependent children and individuals that are blind, aged, or

disabled have access to adequate health care. Connecticut Medicaid provides prescription drug and other health benefits to many thousands of individuals residing in the State.

37. Within the Medical Assistance Program many drugs are paid for on a fee for service basis, in some cases (*i.e.*, Medicaid) with no copayment, and in other cases (*i.e.*, ConnPACE) with a small copayment. This fee for service program includes drugs which are dispensed by pharmacies in accordance with prescriptions. The Medical Assistance Program will pay for fee for service drugs dispensed by a pharmacy after the pharmacy or other provider submits a claim for payment to the Medical Assistance Program or the designated claims payment agent of the Medical Assistance Program.

38. The amount that the Medical Assistance Program pays for drugs on a fee for service basis is governed by various Connecticut laws and regulations governing the Medical Assistance Program and its component programs.

39. Under Conn. Gen. Stat. § 17b-280 and Regulations of Connecticut State Agencies § 17-134d-81b, the Medical Assistance Program generally reimburses fee for service drugs which are dispensed by a pharmacy to a Medical Assistance Program recipient on the basis of: (a) the “federal acquisition cost/federal upper limit ...” (“FAC” or “FUL”) or (b) the “estimated acquisition cost” (“EAC”) as follows: (1) where there is no FAC or FUL the amount reimbursed is the lowest of the EAC, the usual and customary charge or the amount billed, and (2) where there is a FAC or FUL the amount reimbursed is the lowest of the FAC or FUL, the EAC, the usual and customary charge or the amount billed.

40. Under Conn. Gen. Stat. § 17b-280, and Regulations of Connecticut State Agencies §§ 17b-262-448(q), 17b-262-462(j), and 17b-262-611(b)(4), the Medical Assistance Program generally reimburses for fee for service drugs that are administered to a Medical

Assistance Program recipient by a provider on the basis of the EAC. The EAC is utilized by DSS in promulgating fee schedules for providers that administer drugs.

41. Under Conn. Gen. Stat. § 17b-494 and Regulations of Connecticut State Agencies § 17b-490, *et seq.* as modified by Regulations of Connecticut State Agencies § 17b-262-684, *et seq.*, ConnPACE reimburses for fee for service drugs that are dispensed by a pharmacy to a Medical Assistance Program recipient as follows: (1) for the period prior to January 1, 2002 at the “reasonable cost” (defined in Regulations of Connecticut State Agencies § 17b-490(c)) of the drug, minus a copayment, with the option of paying the price paid directly by the pharmacy to the manufacturer for the drug, minus a copayment; and, (2) for the period beginning January 1, 2002, the lowest of (a) the EAC minus a copayment, (b) the FUL minus a copayment, (c) the billed amount minus a copayment, or (d) the usual and customary charge minus a copayment.

42. Under Regulations of Connecticut State Agencies §§ 17-134d-81b(9) and 17b-262-685(12), the EAC is the DSS’s “best estimate of the price as related to the **average wholesale price** generally and currently paid by providers for a drug marketed or sold by a particular manufacturer or labeler, as identified by the national drug code (NDC).” (Emphasis added.)

43. The Connecticut Medical Assistance Program utilizes “Average Wholesale Price” (“AWP”) as a benchmark or reference point to determine the EAC. The term “Average Wholesale Price” is defined by Regulations of Connecticut State Agencies §§ 17-134d-81b(1), 17b-262-685(2) and 17b-262-685(12). Under these regulatory provisions the Connecticut Medical Assistance Program looks to nationally recognized publications or national drug databases.

44. Based upon the above requirements, the Connecticut Medical Assistance Program generally pays or has paid pharmacists and certain other providers an EAC as follows, excluding any applicable copayments: for the period beginning August 1, 2001 at AWP minus 12%, plus a dispensing fee.

45. Defendant McKesson Corporation is a Delaware corporation with its principal place of business at McKesson Plaza, One Post Street, San Francisco, California 94101. McKesson Corporation is the leading provider of supply, information and care management products and services designed to reduce costs and improve quality across healthcare. Founded in 1833, with annual revenues of more than \$50 billion, McKesson ranks as the 18th largest industrial company in the United States.

46. McKesson's unnamed co-conspirator is First DataBank, Inc. ("First Data" or "FDB"), a Missouri corporation with its principal place of business at 1111 Bayhill Drive, San Bruno, California 94066. First Data is a subsidiary of the Hearst Corporation and is the leading provider of electronic drug information to the healthcare industry. For the period of 1998 through about January 2002, when it agreed to divest, Hearst Corporation jointly operated First Data and, its only competitor in the electronic drug pricing market, Medi-Span. As part of the divestiture agreement First Data provided its drug price information to Medi-Span until approximately October 2004.

IV. STATEMENT OF FACTS

47. This case involves the artificial increase in the "markup" factor between the so-called wholesale acquisition cost (or "WAC") and the so-called average wholesale price (or "AWP") of a large number of brand name prescription drugs, a scheme first implemented in late 2001 by McKesson (the largest U.S. pharmaceutical wholesaler) and First Data (the nation's most widely used and "trusted" electronic drug data publisher).

A. Drug Manufacturers and NDCs

48. Drug makers manufacture brand-name and generic drugs. Generally, a drug product that is covered by a patent and thus is manufactured and sold exclusively by one firm is a brand-name drug. After the patent expires, multiple companies can produce the same drug product in the same manner, but the name of the brand name itself remains with the original manufacturer. Drug products not covered by patent protection and produced and/or distributed by many firms are referred to as generic drugs. Manufacturers tend to be either brand-name manufacturers or generic-drug manufacturers, although some manufacture both types of drugs.

49. There are approximately 65,000 branded and generic drug products in the United States market, including different dosages of the same drug. Prescription drugs are dispensed to patients primarily through four different drug distribution channels: (a) retail pharmacies (including national chain pharmacies, independent pharmacies, supermarket chains, and mail order pharmacies); (b) physicians who administer the drug in an office; (c) home infusion (*i.e.*, drugs administered into the patient's bloodstream); and (d) other medical providers. This lawsuit primarily involves branded drugs distributed through the first channel, the retail pharmacies.

50. All drugs intended for retail pharmacy sale are identified by an eleven-digit National Drug Code ("NDC") that is listed with the United States Food and Drug Administration ("FDA"). The NDC is used to identify the drug delivered to the patient. The first five digits of the NDC show the identity of the company that manufactured and/or packaged the drug, the middle four digits identify the drug ingredient and dosage, and the last two digits identify the package size (*e.g.*, whether the bottle of pills contained 100 or 1,000 pills). While there are currently about 65,000 active NDCs, many more NDCs have been issued over time (over the years many drugs and associated NDCs have been phased out).

B. The Wholesale Acquisition Cost

51. Branded manufacturers arrive at an original launch price by taking into account research and development costs, launch and marketing costs, competitor prices and estimates of consumer and physician demand. (Generic makers, of course, generally use commodity pricing approaches.) Once an introductory price has been set, the branded manufacturer establishes the wholesale acquisition cost, or “WAC,” which is used as a baseline for sales to wholesalers (subject to many adjustments, as will be seen). The WAC for branded drugs is then published by the manufacturer.

52. Manufacturers establish the WAC as a baseline for sales to wholesalers and others in the distribution chain. Thus, while WAC may not represent *actual* acquisition cost (as wholesalers may obtain discounts through volume purchases or special deals, and as wholesalers’ customers who also buy based on WAC may receive other price concessions charged back to the manufacturers), it is the baseline for branded drug sales by manufacturers to national wholesalers. In addition, WAC is a publicly available price for most branded drugs. It is the closest reported price to the actual transaction price between a manufacturer and the wholesaler or other direct purchaser of a drug product. Because the wholesalers’ price to the retail class of trade is also typically based on, or is a function of, the WAC, a change in WAC generally results in a similar percent change in price to both wholesalers and to retail pharmacies.

53. WACs are typically reported on invoices between the manufacturer and the drug wholesaler (and as between the wholesaler and the retailer, or between the manufacturer direct to the retailer). Some drug manufacturers have other names for the WAC price such as manufacturer list price, catalog price, direct price, wholesale net price, or book price.

C. The Average Sales Price

54. After all price concessions are considered, a drug manufacturer achieves a net sales price, *i.e.*, a transaction price paid by a pharmacy or provider when purchasing a drug product from either a drug manufacturer or wholesaler. The net sales price takes into account the invoice price and all on-invoice, as well as off-invoice adjustments for discounts, rebates, purchasing allowances, or other forms of economic consideration.

55. Of course, manufacturers can (and do) calculate for internal purposes the net sales price at which they are able to sell their products. The average of those net sales prices is usually called the average sales price (or “ASP”). While net acquisition prices and associated ASPs are known to each drug manufacturer, they are not typically published or made public.¹ Some drug manufacturers may have a variety of terms for specific discounts that are based on class of trade, volume of purchase, market share movement, preferred formulary status, terms of payment, and other criteria. Because ASP is meant to be the net price after all forms of discounts, rebates, purchasing allowances or any other forms of economic consideration have been taken into account, discounts that contribute to ASP are considered proprietary and confidential by drug manufacturers. As a result, for retail pharmaceutical products the exact relationship of ASP to WAC (or to the average wholesale price or AWP, discussed below) for a particular drug at a particular point in time is not publicly known.

D. The Average Wholesale Price

56. In addition to causing to be published a wholesale acquisition cost or WAC for branded drugs, over the years branded (and generic) manufacturers have also caused to be published an average wholesale price (or “AWP”) for prescription pharmaceuticals. The average

¹ The important exception to this is Congress’ recent enactment of the Medicare Modernization Act of 2003, in which Congress changed the Medicare reimbursement system for drugs and biologicals from an AWP-based system to an ASP-based system physician-administered. This exception is not relevant here.

wholesale price or AWP is a list price used for invoices between drug wholesalers and pharmacies (or other appropriate drug dispensers, such as doctors for physician-administered drugs) and is typically used as a benchmark for the reimbursement by End Payors (such as SFHP) to dispensers (such as retail pharmacies or doctors) for drugs provided to patients. Historically, the AWP is set directly or indirectly by the drug manufacturer, with an effective date and remains in effect until a change in price is published.

57. WAC and AWP differ in that they represent list prices at different levels in the market. WAC represents a list price from manufacturer to wholesaler, while AWP represents a list price from wholesaler to dispenser (*e.g.*, pharmacy, physician, hospital, or other provider).

E. The WAC-to-AWP Spread

58. In the pharmaceutical industry, the amount by which the AWP exceeds the WAC is sometimes known as the WAC/AWP “markup” or “spread” for a particular drug product.

59. The relationship between AWP and WAC is sometimes expressed as the percentage by which the difference is above WAC (*e.g.*, 20% or 25% above WAC, usually called “the markup”).

60. For many years preceding the scheme alleged in this Complaint, the WAC-to-AWP spread for branded drugs had predictably set patterns, and the competitive pricing marketplace for pharmaceuticals had adjusted and accommodated for those patterns. For branded pharmaceuticals, the WAC/AWP markup tended to fall in two quantum places: 20%, and 25%. In other words, in the many years preceding the Scheme alleged in this case, a particular branded drug NDC would carry both a published WAC (*e.g.*, \$100 for a 100 count bottle) and a published AWP at either 1.16 or 1.20, or 1.25 of the WAC (*e.g.*, \$120).

61. These standard 20%, and 25% WAC/AWP markup factors, were commonly associated by McKesson, First Data and others in the pharmaceutical industry with particular

divisions of pharmaceutical companies. For example, a pharmaceutical division might be designated as a “20% markup” company, while another company working in a different therapeutical area, would be designated as a “25% markup” company.

62. Another predictable aspect of brand drug prices over the years was the *unchanging* nature of the WAC/AWP markup for a particular NDC. In other words, if a particular NDC first launched at a 20% markup value, that NDC would remain as a 20% drug during the lifetime of that NDC, almost as if it were part of the genetic code for that NDC. Thus, the WAC and AWP for that drug moved in parallel fashion (usually up), keeping the same markup factor associated with that NDC. *Indeed, prior to the scheme alleged in this case, it was extraordinarily rare for the WAC/AWP spread to be changed for any particular NDC.*

F. Drug Wholesalers

63. Branded manufacturers’ primary customers are wholesalers, although to a much broader extent, manufacturers also sell directly to retail pharmacy chains, mail-order pharmacies, hospital chains and some health plans. Wholesalers are manufacturers’ largest group of purchasers, and wholesale prices depend partially on volume purchased.

64. Like most other types of wholesalers, pharmaceutical wholesalers purchase goods from manufacturers and then resell them to other purchasers. Wholesalers, whose main customers are retail and mail-order pharmacies, buy pharmaceuticals in large quantities, sort them by customer needs and disperse them in usable quantities.

65. The price wholesalers pay to manufacturers for any given product at any given time can fluctuate with the quantity purchased. The manufacturer may quote a wholesaler a price close to or at WAC, however, there is often a small volume discount or early cash payment discount off that price.

66. National wholesalers are the primary intermediate level in the distribution process retail channel. They account for 45.7% of prescription drugs (\$98.5 billion) in 2002. Other intermediate channels of distribution include chain warehouses with 32.3% (\$69.8 billion) of the market, regional and specialty wholesalers with 9.3% (\$20.2 billion) of the market, and group purchasing organizations that usually contract with a wholesaler to perform the distribution function on their behalf. Only about 12% of prescription sales by drug manufacturers are made directly to providers (*e.g.*, physicians or hospitals) or pharmacies.

67. Wholesale drug distribution is heavily concentrated. The three largest wholesalers are the defendant McKesson, Cardinal Health, Inc. (“Cardinal”) and AmeriSource Bergen Corporation (“ABC”). Each of these “Big Three” wholesalers has slightly less than one-third of the national market of prescription drug wholesale distribution. Collectively, they account for more than 80% of drug sales that flow through drug wholesalers (national, regional, and specialty).

G. Wholesaler Sales Transactions

68. National drug wholesaling is generally perceived as price competitive, with McKesson, Cardinal and ABC (or their predecessors) competing for business with retailers (primarily major chain drug retailers, independent pharmacies, supermarket drug retailers, and mail order businesses). As a result, drug wholesaler margins to retailers tend to be thin (even at times non-existent), with a significant portion of national drug wholesaler revenue instead being derived from prompt pay discounts received from manufacturers and from wholesaler inventorying measures that anticipate price increases.

69. National drug wholesalers sell branded drugs to the retail class of trade based on prices pegged to the WAC. Given the tendency for narrow margins in the national drug wholesaling business, the published WAC for a manufacturer’s retail-channel branded drug is

not only a strong market indicator for the wholesaler's buy-side cost for a branded drug, it is also expected that the WAC, subject to certain adjustments, is a reasonable benchmark of the sell-side costs charged by national wholesalers of branded drugs to major pharmacy retailers.

H. Retail Pharmacy Channel

70. The retail pharmacy channel (including chain drug store companies, independent pharmacies, mail orders and supermarkets), comprise roughly two-thirds of the estimated market share of dollars for prescription drugs. Currently, the four largest drug store chains account for most of the retail pharmacy market share today, and the recent consolidation trend appears to be continuing. Some large national or regional retail chains (including pharmacy, supermarket, mass-merchandise chains) purchase drugs in large enough volumes so that they can bypass the wholesaler and buy directly from the manufacturer, but these direct purchases remain a small portion of the overall picture.

71. Regardless of whether the retail pharmacy is large or small, its purchase of prescription drugs is typically based using WAC as a benchmark, although that benchmark is subject to adjustments such as a variety of discounts, rebates, and direct or indirect offsets to pricing.

72. When large chain pharmacies buy directly from manufacturers, manufacturers offer these pharmacies both up-front discounts for purchasing their products and back-end discounts and formulary rebates to selling specific volumes of drugs or achieving a certain share of a specified market. When purchasing drugs directly from manufacturers, pricing using the same WAC benchmark system, but the actual transaction cost varies considerably from the WAC given these other arrangements.

73. Smaller retail entities, such as independent retail pharmacies and regional retail chains, purchase directly from wholesalers or joint group purchasing organizations ("GPOs") in

order to leverage their combined purchasing power. Some of these groups further reduce their costs through direct rebate deals offered by manufacturers. In making purchases from wholesalers, resellers and manufacturers, the starting benchmark for transactions is the WAC but, again, the actual transaction cost is highly variable due to the additional arrangements.

74. In short, entities in the retail distribution chain (including wholesalers, resellers (retailers), retail chain pharmacies, independent pharmacies, mail order houses, and GPOs) purchase brand-name drugs based upon WAC. While the actual transaction purchase price varies from the WAC, WAC acts as the actual baseline for the many millions of transactions by which entities in the retail distribution chain acquire branded drugs.

I. The Private End Payors for Prescription Drugs

75. At the most basic level, prescription drug expenditures are funded by either private or public sources. In the United States, more than \$200 billion dollars is spent annually on prescription drugs. About three quarters of this amount is privately funded.

76. Private payors for prescription drugs include drug benefit plan sponsors and consumers. The drug benefit plan sponsors (who pay for part or all of the cost of prescription drugs for their covered beneficiaries) include self-insured employers, health and welfare plans, health insurers and managed care organizations (MCOs). Most of these plan sponsors reimburse retailers (for retailers' drug purchase costs) through pharmacy benefit administrators (either health plans or pharmacy benefit management companies) who negotiate discounts with retail pharmacies and rebates from drug manufacturers. The vast majority of such purchases are for out-patient drugs that are self-administered, *i.e.*, drugs distributed through the retail distribution channel.

J. End Payors Drug Reimbursements are AWP-Based

77. Although retail pharmacies *purchase* pharmaceutical products based upon pricing formulae that employ the WAC, retail pharmacies *get paid* (*i.e.*, receive reimbursement) from plan sponsors and consumers based upon an AWP reimbursement formula plus a dispensing fee. This is a fundamental anomaly of the retail distribution channel for drug products – that retail pharmacies’ *purchases* are based on prices pegged to the published WAC, but retail pharmacies’ *reimbursements* or charges are based on the published AWP.

78. Health plans typically contract with intermediaries called pharmacy benefit managers (“PBMs”) to negotiate prices with manufacturers and retail pharmacies and thereafter adjudicate the numerous transactions that occur during the administration of a plan. Although the PBM negotiates prices and adjudicates claims, the plan sponsor (*i.e.*, insurer, self-insured employee, health and welfare plan) remains at risk for the charges paid to retail pharmacies and mail orders. In the contracts between PBMs and plan sponsors, the retail pharmacies’ drug ingredient costs for brand-name drugs are reimbursed at the AWP less a certain percentage, or “discount.”

79. Brand drug reimbursement for retail pharmacy ingredient cost contained in the contracts between PBMs and plan sponsors, and PBMs to pharmacies, use an AWP-based reimbursement structure. For example, since 2002, Express Scripts’ standard form contract has expressly stated that its reimbursement formula is based on AWP from the “current information provided to ESI by drug pricing services such as First Data Bank. . . .” Similarly, Caremark’s website states: “For both brand and generic drugs, the pricing formula at retail and mail is based on the discounted Average Wholesale Price (AWP) as reported by First Data. Caremark loads First Data’s updated data into the system on a daily basis.” Other PBMs expressly utilize First Data’s published AWP as the source of AWP pricing to be utilized in payment.

80. The AWP-based reimbursement benchmark for private payments to the retail class of pharmaceutical trade has long been acknowledged. Most recently, at a hearing on December 7, 2004, before the United States House of Representatives Committee on Energy and Commerce, a former Senior Vice President of Aventis Pharmaceuticals, testified that “AWP has been codified as the benchmark price, by statute and regulations, in the public sector and by contract in the private sector.” Those paying for drugs, by statute or contract rely on and use the published AWP.

81. Third-Party AWP-based reimbursement has also been acknowledged by McKesson. For example, in September 2001, Robert James of McKesson, internally noted that “I think it is important to understand that the AWP’s that are used for third party reimbursement are the First Data Bank (“FDB”) AWP’s.” MCKAWP 0068514.

82. In summary, thousands of pharmaceutical reimbursement contracts are based on AWP minus a specified discount. As a result, a leading expert on pharmaceutical pricing has concluded that “AWP is the glue that binds the system of pharmaceutical reimbursement rates. All or predominantly all, reimbursement rates for pharmaceuticals purchased under public sector and private drug benefit insurance plans are negotiated based upon AWP and discounts from AWP.” Public and private payor reliance on AWP was well known to McKesson.

K. Medicaid Drug Reimbursements are AWP-Based as are Connecticut’s Payment

83. Public purchases for prescription drugs provide a variety of programs for low-income and elderly patients, veterans, members of armed services, and federal, state and local government employees. These public payors also rely on and use AWP as a basis for reimbursement to pay for dispensers’ ingredient costs for branded pharmaceutical products.

84. Medicaid has the most significant impact on prescription drug pricing for out-patient drugs. The Medicaid Program, jointly financed through federal and state funds, is

designed to aid certain low-income people and the disabled, and covers about 40 million individuals. Between 1997 and 2002, Medicaid expenditures for prescription drugs in the fee-for-service part of the program increased at an average annual rate of 18%, going from \$10.2 billion to \$23.4 billion. (While these are significant sums, they amount to less than 10% of the overall annual prescription drug expenditure.)

85. Medicaid's reimbursement system relies upon the published list prices of drugs (which are largely directly set by manufacturers) to determine pharmacies' reimbursement. States reimburse pharmacies using formulas that are typically based on the average wholesale price or AWP of a drug. For example, a state might reimburse a pharmacy 85% to 90% of the average wholesale price of a drug plus a fixed dollar amount of \$3 to \$5 (as dispensing fee) to cover the pharmacy's other costs.

86. Connecticut routinely provides prescription drug coverage as part of its Medical Assistance Program for medical assistance to the poor, needy, elderly and disabled. Included in that coverage are payments for drug products, including both single source drug products (brand-name drugs) and multi-source drug products (generally generic drugs), that are delivered to the patient either by providers including pharmacies and physicians incident to their services.

87. Connecticut's Medical Assistance program's reimbursement rates at all times relevant to this Complaint have been based on price data as published by FDB or other price reporting services.

88. During all relevant times covered by the Complaint:

(a) Connecticut's Medical Assistance program has relied on FDB or Medi-Span as its primary source of pricing data and has utilized reports of AWP, DP, and the Federal Upper Limit ("FUL") supplied by FDB or Medi-Span.

(b) FDB reported AWP, DP, wholesale acquisition costs (“WACs”) and FULs for the specific prescription drugs based on the price information provided by the defendant for the respective drugs.

(c) Medi-Span reported AWP, DP, wholesale acquisition costs (“WACs”) and FULs for the specific prescription drugs based on the price information provided by FDB for the respective drugs.

89. McKesson caused to be reported false or misleading prices to Connecticut’s Medical Assistance program by providing false or misleading price information to FDB with knowledge that they in turn would utilize such false and misleading price information in determining the AWP that were reported to Connecticut.

L. Medicare Drug Reimbursements are AWP-Based

90. The other significant public purchaser for prescription drugs is the federal Medicare Program.

91. Until recently, the Medicare Program generally did not cover the cost of out-patient prescription drugs that a Medicare beneficiary self administers (*e.g.*, by swallowing the drug in liquid or pill form). However, Medicare Part B does cover approximately 450 drugs, including injectables administered directly by a doctor, certain oral anti-cancer drugs, and drugs furnished under a durable medical equipment benefit.

92. Medicare Part B reimburses medical providers 80% of the allowable amount for a drug. The remaining 20% “co-payment” amount is paid by the Medicare Part B beneficiary. All medical providers are required by law to bill the 20% co-payment and make attempts beyond merely billing to collect that amount. Moreover, before Part B benefits are payable, beneficiaries under Part B are required to pay an annual deductible amount.

93. Some Medicare beneficiaries can purchase private Medigap insurance, which covers, among other things, all or part of the 20% co-payment for Covered Drugs.

94. For many years up to and through 1997, Medicare's reimbursement system for the relatively narrow band of physician-administered drugs sought to estimate providers' acquisition costs by pegging reimbursement to either the estimated acquisition costs or to the national average wholesale price sale price. In practice, carriers that administered the Medicare Program reimbursed physicians and clinics for physician-administered drugs covered by Medicare on the basis of the published wholesale price or AWP.

95. Beginning in 1998, Medicare's practice of reimbursing based upon the published AWP was codified by statute and implemented by regulation. Beginning in 1998 and until recently, Medicare reimbursed for drugs and biologicals under its program of the reimbursing physician-administered drugs based upon 95% of the published average wholesale price.

96. At the end of 2003, Congress enacted the Medicare Modernization Act. Among other things, the Act changed the AWP-based reimbursement system for Medicare to a system based upon each manufacturers' actual calculation for the average sales price for each drug or biological covered by the program. Interim rules transitioned the AWP-based system with modifications to the percentage off of AWP. Beginning in 2004, Medicare has been transitioning to an ASP-based reimbursement system.

97. In summary, the two largest public purchaser programs for prescription pharmaceuticals – Medicaid and Medicare – historically relied upon published average wholesale prices as the fundamental basis upon which to reimburse for branded drug ingredient costs incurred by dispensers (retail pharmacies for Medicaid, and medical providers in the Medicare area).

M. PBMs

98. Third-Party Payors (“TPPs”) do not typically look at AWP-WAC but look instead to overall price trends. This is because most TPPs do not negotiate directly with retail pharmacies to set their rate of reimbursement, but contract with Pharmacy Benefits Managers (“PBMs”), who act as the middlemen between TPPs and pharmacies. But PBMs make very little money processing TPP claims and look to other sources for generating revenue. For example, in its 2005 Annual Report, Express Scripts, Inc. reports that it receives 35% of its revenue from mail order operations compared to 1% from services offered to TPPs.² Similarly, in its 2005 Annual Report, Medco identifies client services as less than 1% of its overall revenue, while its mail order business accounts for 37%. One observer recently explained the evolution of PBM services and competition as follows:

Initially, the goal of the PBM was to simplify the administration of benefits for health plan members and to provide some cost-management services. . . . In the early 1990s, as electronic point-of-sale (POS) claims processing became prevalent, PBMs began to shift their dependence on revenue from claim processing to other sources, including manufacturer rebates, selling data to manufacturers, and selling mail order and retail drugs. PBMs found that health plans and employers were more interested in lower administrative fees, because the result of pharmacy-cost reduction appeared to be too difficult to measure. This practice created a price war among PBMs for business from large health plans and resulted in a perception of POS pharmacy claims as a commodity. . . . ***Gradually, the PBM industry shifted to aggressive strategies of seeking revenues from alternative sources to compensate for selling benefit administration services at lower costs.*** PBMs that could not buy or build mail order capabilities quickly turned to other revenue sources. These included the sale of claims data to drug manufacturers and repricing of the retail network, known as spread pricing (fees gained through continual negotiation of lower rates with the pharmacy network that are not passed on to the health plan or

² Express Scripts 2005 Annual Report.

employer). *Today, revenue from POS claims processing provides little to no margin for PBMs.*³

99. Mail order services are a particularly lucrative source of revenues for PBMs. In their mail order capacity, PBMs stand in the same shoes as McKesson's retail pharmacy clients by profiting from the WAC-AWP increase. Thus, PBMs had a strong incentive to remain silent about the scheme or risk losing additional profits stemming from new markups.

N. U&C Payors

100. Additionally, there is a significant portion of the population who are uninsured or underinsured and who pay for drugs in cash. This is referred to in the industry as the usual and customary ("U&C") charge.

101. U&C payments are tied to the reported AWP, and are usually set at a price above AWP or at a minimum above the pharmacy's AWP-based Third-Party reimbursement formula. Hence an artificial increase in the AWP uniformly impacts such consumers.

102. These are the most vulnerable of all consumers purchasing drugs. They have no power to negotiate discounts.

O. The Brand Drug Pharmaceutical Market was Conducive to a Price Fixing Scheme

103. The market for brand-name prescription drugs has a number of features that facilitated the implementation of the price-fixing conspiracy alleged in this Complaint. The industry relies almost exclusively on electronic publishers for the source of AWP, especially First DataBank. Additionally, for the period of 2001 through late 2004, First DataBank and Medispan acted as one for the purposes of calculating and publishing AWP: "This means that essentially the Medispan data is the First DataBank data." MCKAWP 0057415. First Data was therefore the industry standard bearer for both AWP, and by implication, AWP-WAC markup.

³ Steve Martin, "PBM Industry Today: Who's Managing Drug Costs?", *Managed Care Magazine*, Dec. 2001, <http://www.managedcaremag.com/archives/0112/0112.pbmfuture.html>, accessed August 29, 2007 (emphasis added).

104. During the time the scheme was implemented, First Data purported to use a so-called survey of the major wholesalers, but as a matter of policy, First Data refused to share the responses to its so-called surveys even when questioned by manufacturers or others concerned about changes to their traditional markup. Further, in this same time frame, Cardinal and Amerisource did not participate in the so-called surveys as a matter of policy. Their own list prices adhered to the manufacturer's suggested or historical markup, *i.e.*, they did not comport with First DataBank's increases – although in some instances, at a much later date, they changed their markups to be consistent with First DataBank's. First Data's secretive process of alleged "surveys," involving only McKesson, allowed McKesson to systematically "normalize" brand drug markups at 25%. Additionally, the effects of the scheme were further obscured because First DataBank stored its markup information separately from its database of published prices and generally increased the markup on individual drugs only when the manufacturer announced a price change to the WAC. Most TPPs do not track changes to markups, particularly not markups on brand-name drugs. Moreover, the market participants most likely to have observed these changes, the retail pharmacies and PBMs, directly benefited from the scheme and were therefore loathe to disclose them to End Payors.

P. Private and Public End Payors Rely on Published Drug Pricing Compendia

105. The private and public pharmaceutical reimbursement systems have at their core critical dependence and reliance upon accurate and timely publication of the current AWP for every active formulation of drugs dispensed by retail pharmacies in the country, given the breath of this dependence (private insurance systems covering more than 200 million lives as well as millions of cash payors); the healthcare system's growing reliance on pharmaceutical products as a treatment of first resort; and the scores of thousands of available drugs on the market. Private (and public) reimbursement systems, including the plan sponsors and consumers who reimburse

drug dispenser costs, also rely upon pharmaceutical pricing publishers to accurately and fairly publish AWP and WACs for NDCs. McKesson and FDB were aware of this reliance.

106. Several pharmaceutical industry compendia periodically publish the AWP for active NDCs in the United States. Generally these publications are available in either hard copy format or in electronic media.

107. Generally speaking, the two printed compendia include Drug Topics Red Book (the “Red Book”) (published by Thompson Healthcare) and American Druggist First Data Bank Annual Director of Pharmaceuticals and Essential Director of Pharmaceuticals (the “Blue Book”) (which for several years has been defunct). While the Red Book is used to determine published AWP (primarily for physician-administered drugs), and while certain limited electronic information is available regarding Red Book published prices, the Red Book remains primarily an annual printed publication with periodic printed updates.

108. In periodically announcing the AWP for each drug, publishers generally report prices that are supplied to them by manufacturers for their respective drugs. For instance, the forward to the 1999 edition of the Red Book states that “all pricing information is supplied and verified by the products’ manufacturers, and it should be noted that no independent review of those prices for accuracy is conducted.” In addition, a June 1996 Dow Jones news article reported that Phil Southerd, an associate product manager of the Red Book, stated that Red Book only publishes prices that are faxed directly from the manufacturer.

Q. The Emergence of First Data and MediSpan as Electronic Data Publishers

109. In addition to printed publications of pharmaceutical prices, the AWP for NDCs is also widely made available to manufacturers, wholesalers, retailers (including major chain pharmacies, independents, mail orders), pharmacy benefit managers and Third-Party Payors,

(*i.e.*, plan sponsors of drug benefit plans such as insurers, Taft-Hartley Funds and self-insured employers), through large electronic drug databases.

110. Drug databases started back in the mid-1970s with the advent of significant drug benefit programs. These programs, along with the pharmacists who are dispensing the drugs and the Third-Party Payors (primarily insurance companies) who are paying for them, needed comprehensive and accurate descriptive and pricing information to ensure the accuracy of the claims they were paying.

111. The processing of claims became a massive job as drug prescriptions increased. The need for a consistently accurate and comprehensive drug price database became a major need. As First Data documents acknowledge, the “specter of inaccurate drug prices drove the database companies to develop techniques to assure the accuracy and comprehensiveness of the data.”

112. During the 1990s, there were only two major electronic drug database companies: (1) First Data, which describes itself as “started as the only purely electronic database company;” and (2) MediSpan, which had its roots in the printed drug price catalog business.

113. The principal products sold by First Data are based upon information contained in its National Drug Database Files, or “NDDF.” The NDDF is a massive electronic database dating back many years and containing scores of fields of information for both active and non-active NDCs. Among many other pieces of quantitative and non-quantitative information contained in the NDDF, are the current and each historical WAC (known in the NDDF as the wholesale net price, or “WHN”) and AWP (set forth in various fields, including an AWP field designated by First Data as Blue Book AWP or “BBAWP”) for each NDC.

114. The principal electronic database products sold by MediSpan are based upon its Master Drug Database Files or “MDDF.” The MDDF electronic database is smaller than the NDDF, but nevertheless contains numerous fields of data for each NDC, including current and historical WAC and AWP. Both the NDDF and the MDDF are comprehensive, intragatable drug information databases.

115. Comprehensive, intragatable drug information databases (“intragatable drug data files”) are electronic databases containing purportedly comprehensive clinical, pricing, and other information on prescription and non-prescription medicines. Intragatable drug data files are uniquely capable of being readily integrated with other computerized information systems to help pharmacists and Third-Party Payors quickly obtain information important to decisions regarding the prescription, dispensing, price reimbursement and purchase of medicines, and also to automatically provide drug information that patients need for safe use of their drugs. Retail pharmacies and PBMs usually use intragatable drug data files to determine Third-Party Payor reimbursement (when using AWP fields), as well as their own acquisition costs (when using WAC fields).

116. Drug information in other forms is usually not an adequate substitute for the provision of much information obtainable only in intragatable drug data files. For example, a pharmacist filling a prescription can more quickly and reliably check for harmful drug interactions through an instant, automatic check of a drug data file when he or she enters the prescription into the pharmacy’s computer system, than through consulting a separate, unintegrated, and less up-to-date information source such as a book or data on a compact disk. Relying on such a separate reference would be more time-consuming, and would increase the

risk that a harmful drug interaction would not be detected until after the patient purchased and used the drug.

117. During the 1990's and up to 1998, First Data and MediSpan were substantial, direct competitors within the relevant market of intragatable drug data files in the United States. They faced little or no competition from other firms. Until 1998, two electronic drug databases – First Data's NDDF and MediSpan's MDDF – played the integral role in providing essentially all electronically-based drug reimbursement transactions in the United States. They accounted for billions of transactions each year and many billions of dollars of payments.

118. Of course, First Data's NDDF and MediSpan's MDDF both contained critical price point data fields for the approximate 65,000 NDCs then active in the marketplace.⁴ The retail class of trade relies on these systems for health and reimbursement among the data fields for each active NDC (in the NDDF and the MDDF) information, using the AWP for the associated NDC when seeking reimbursement for drug ingredient cost.

R. The Merger of First Data and MediSpan Systems

119. In 1998, the Hearst Corporation caused First Data to be merged with the smaller MediSpan. After the merger, First Data began the process of combining its NDDF with MediSpan's MDDF (resulting in a product sometimes known as NDDF Plus). Through this process, the Hearst Corporation caused First Data to become the sole United States provider of intragatable drug data files, including the publication of electronic drug database pricing information such as the WAC and associated AWP for branded pharmaceutical products. Thus, beginning in or around 1998 and thereafter, virtually every participant in the pharmaceutical distribution chain who used electronic database systems in undertaking reimbursement

⁴ First Data's NDDF also contains historical information and thus, it contains data for almost 200,000 NDCs since many are no longer active in the marketplace.

transactions for billions of dollars of pharmaceutical products used and relied upon the accuracy of data from First Data's NDDF and MDDF, including the published WAC and AWP price fields.

120. In 2001, the Federal Trade Commission (after a lengthy investigation) brought suit against the Hearst Corporation and First Data claiming, among other things, that the First Data and MediSpan merger had been unlawful. Shortly thereafter, the Hearst Corporation agreed to divest its MediSpan assets, culminating in a consent decree late that year. But by this time, First Data's merger of the NDDF and MDDF, along with changes of personnel and related systems effectuated over the prior three years, was nearly complete. As a result, as part of First Data's divestiture of the MediSpan assets, First Data was required to provide the purchaser of the MediSpan assets with transitional and editorial services for many years into the future.

121. As a practical matter, pricing data contained in both the NDDF and the MDDF post-divestiture remained the same. Since 1998 and despite the late 2001 divestiture, First Data has functioned as the sole editor of data populating the only available comprehensive intragatable electronic drug data systems (the NDDF and the MDDF) for branded drug pricing information used in the United States for reimbursement transactions in the retail pharmacy channel.

122. All changes in FDB's electronically published AWP's and WAC-to-AWP spread were the same. The Consent Decree that implemented the Medispan divestiture from FDB required that FDB continue to provide Medispan with all FDB pricing information until Medispan (now called Facts and Comparisons), could develop its own pricing production system. Thus, during the time period including August 1, 2001 to present, when the scheme

effectuated an increase in FDB's published spread, this increase also occurred in Medispan's published prices. FDB and McKesson knew this would be a consequence of the scheme.

123. During the 1990s and up to the end of 2001, both First Data and MediSpan maintained the historical proportion between AWP and WAC when branded price increases were announced. This enabled the publishers (when receiving, for example, information only regarding WAC changes to a branded drug) to automatically calculate the corresponding AWP. As a result, the marketplace had predictability and marketing pricing dynamics adjusted according to that expected practice.

S. First Data Gains the Trust of the Pharmaceutical Industry

124. Prior to and throughout the time period including August 1, 2001 through the present, pharmaceutical End Payors operated on the belief that the AWP's were the result of honest reporting both by pharmaceutical companies, with respect to the publication of their WACs or submission of their suggested AWP's to publishers, and by an empirical and professional analysis undertaken by First Data or MediSpan.

125. The reliance upon the accuracy and legitimacy of First Data's data was not only known to First Data, but was the foundation of its business model, marketing and promotion plans. For example, First Data stated:

-- "For over two decades, healthcare professionals have come to depend on First DataBank's comprehensive knowledge bases to deliver the timely, accurate drug information they need to support their business and clinical decision-making."

-- "Thus developers can respond quickly to their customers' demands for reliable, easy-to-access drug information, available on multiple platforms.

-- "[First Data:] A partner you can trust."

-- Trusted Drug Knowledge...Comprehensive drug knowledge bases that have been trusted for decades by healthcare professionals – in thousands of installations – to provide the

timely, accurate information they need to support their clinical and business decision-making.

126. First Data promoted its pricing information as “accurate,” of “high-quality,” and as “set[ting] the standard in the healthcare industry for comprehensive coverage of descriptive, pricing and clinical information on drugs.” It also recognizes that its pricing information is “relied upon by professionals in th[e] industry,” and that, “[t]o be useful to its audience, *First Data’s data must be accurate and up-to-date.*”

127. In pleadings filed in the *In re Pharmaceutical Indus. Average Wholesale Pricing Litig.*, MDL No. 1456 (D. Mass.), First Data admitted that buyers and sellers in the pharmaceutical marketplace rely on its pricing data: “FDB knows the pharmaceutical industry well and is relied upon by professionals in that industry to report reliable information.”

128. Throughout the 1990s, First Data gained the trust and reliance of participants in the pharmaceutical marketplace – most notably pharmacies and the Third-Party Payors that reimbursed them – upon First Data’s electronic publication of AWP for each active NDC.

129. Throughout this time, First Data knew, of course, that the primary purposes of publication of the WAC and of the AWP, and of the associated WAC-to-AWP markup (embedded in the difference between the AWP and WAC data fields), was to serve as an electronic basis for the mass-reimbursement of retail pharmacies for thousands of daily transactions and billions of yearly transactions. After all, First Data acknowledged: “AWP was developed because there had to be some price which all parties could agree upon if machine processing was to be possible.” As First Data stated: “AWP represents the average wholesale price; the average price a wholesaler would charge a customer for a particular product. The operative word is *average*. AWP was developed to provide a price at which all parties could agree upon for electronic processing to be possible.”

T. First Data's Representations to Gain Marketplace Reliance on Its Pricing Data

130. First Data gained this reliance upon the empirical integrity of its electronic publication of AWP due to representations it made to its customers and others in the pharmaceutical marketplace regarding how First Data populated WAC and AWP information fields.

131. Among other things, First Data held out that its electronic databases contained accurate field information for each NDC's AWP. Emphasizing that as to the AWP the "operative word is *average*" (First Data's emphasis), First Data indicated that its empirically derived information was obtained directly from its specific contacts "within each major drug manufacturer/labelers organization." First Data represented that when it was apprised that the AWPs suggested by manufacturers were also those used by the wholesalers, First Data published as the AWP the exact AWP that had been suggested by the manufacturer. On other occasions, First Data represented that its AWPs were based upon empirically determined markup factors obtained by First Data after it undertook a comprehensive and sound survey. In these situations, while the manufacturer effectively established both price points (the WAC and the AWP, since the manufacturer established the WAC and knew of the existing mathematical markup factor resulting in the AWP), First Data held out that its markup factors had been corroborated through empirical research of wholesalers' actual markup of WAC to AWP.

132. During these years, First Data published information regarding how it derived the markup factors for the WAC-to-AWP spread. This information always emphasized the empirical nature of the data populating its electronic database. Thus, First Data represented:

- That industry changes "have made the wholesale survey fundamental in maintaining current pricing data";
- That when a manufacturer had not provided a suggested wholesale price for a new product, "wholesaler surveys" were

undertaken in order to derive an empirically based markup actually used by wholesalers;

-- That wholesaler surveys were also undertaken in order “to confirm that the markup that First DataBank utilizes for AWP is representative of the wholesaler industry”;

-- In the early 1990s, First DataBank represented that it “surveys a minimum of five drug wholesalers that represent over two-thirds of the total dollar volume of drug wholesalers,” and that the “number of surveys performed is increasing”;

-- Throughout the 1990s, and again in order to paint a picture that the markups are empirically derived, First DataBank represented that because “individual wholesalers may markup each manufacturer differently, a weighted average, not a consensus average, is calculated,” and that then “the market share held by the wholesalers surveyed affects the markup proportionally,” and that thereby “a higher degree of certainty is achieved.”

-- While in most cases the “surveys” matched current data, where they did not, “it is the policy that First DataBank will change the markup on file to report marketplace reality.”

133. First DataBank’s representations and marketing efforts regarding empirically driven markup factors obtained by “wholesaler surveys” continued throughout the 1990s. A late-1990, widely published editorial by First Data regarding AWP pricing stated:

Average Wholesale Price

I have many conversations regarding what is “AWP” and how does FDB determined [sic] it. There is much folklore and misunderstanding as to the determination of AWP and where we get the data. AWP is the average wholesale price. That is, AWP is the average of the prices charged by the national drug wholesalers for a given product (NDC). The operative word is average. AWP was developed to provide a price which all parties could agree upon for electronic processing to be possible.

In order to determine the AWP, First DataBank surveys national wholesalers to ascertain what they use as a price basis in their AWP files. We contact the wholesalers to determine what the markup should be for a new company or to confirm that the markup that we are applying is current. A survey may be performed on a single NDC number or for a manufacturer’s entire line of products. In either case, each national wholesaler is surveyed on a number of products from each manufacturer.

The number of surveys performed is increasing. First DataBank surveys drug wholesalers that represent over two-thirds of the wholesaler total dollar volume. The markup that First DataBank utilizes is representative of wholesalers on a national level. Because individual wholesalers may mark up each manufacturer differently, a weighted average, not a consensus average, is calculated. That is, the market share held by the wholesalers surveyed affects the markup proportionally. Wholesalers with higher drug dollar volumes have more weight in the determination of the final markup. Thus, a higher degree of certainty is achieved. We also consider the manufacturer's suggested wholesale price (SWP) in our determination.

Many are under the impression that the manufacturer sets the AWP. FDB considers the wholesale price suggested by the manufacturer a "Suggested Wholesale Price (SWP)" and has a different data element called "SWP" on the NDDF file for those customers who chose to use the SWP instead of AWP. Frequently, the SWP and AWP are the same; however, we are having more instances where they are differing. We will populate the SWP with the new markup, but will survey the national wholesalers to determine AWP. The AWP will be populated with the wholesaler survey price even if it disagrees with the SWP.

In most cases, the results from surveys match what First DataBank is using. In the instances that they do not, it is policy that First DataBank will change the markup to report marketplace reality. (Emphasis added.)

134. First Data's representations regarding the accuracy of its electronic publication of AWP were highly successful. By 1998, after its acquisition of its only competitor, MediSpan, First Data was the sole provider of comprehensive, intragratable electronic data files providing AWP information throughout the retail pharmacy distribution chain, including most private Third-Party Payors. Of course, First Data made this known when marketing its products, stating that it "provides you the same AWP prices used by Aetna, PAID PCS, MEDI, MET, most Blue Cross Blue Shield Plans, wholesalers and approximately 49 Medicaid programs."

U. In the Late 1990s, Retailers Looked to the WAC/AWP Spread to Increase Margin

135. Also during the 1990s, national wholesalers and drug retailers continued to report significant declines in margin, despite an overall escalation in drug costs. In order to address escalating healthcare costs, including the significant rise in prescription drug expenditures,

Third-Party Payors and managed care organizations had, to some extent, placed significant pressure on national wholesalers and the retail distribution industry, causing widely reported reductions in wholesaler and retailer margins.

136. With this increased pressure on margin, retail pharmacies began to look for ways to stave off the reduction. To insiders in the pharmaceutical industry, it has long been recognized, as one manufacturer has stated, that “the AWP-WAC spread is the primary determinant of the end retail pricing of prescription drugs. As a result, changes in the spread will have a direct impact on retailer profitability as well as drug expenses for not only consumers but even more uniformly for health insurers and other third party payors.”

137. Another industry insider stated:

Payors currently use AWP or average wholesale price as a basis for reimbursing retail pharmacy for providing RX's to patients with insurance and by retail pharmacy as a basis for pricing cash prescriptions. Pharmacy reimbursement – a higher spread translates into higher reimbursement to retailers and mail order pharmacies. The usual reimbursement formula for private third party Medicaid RX's is anchored off of AWP – so a higher markup will increase the reimbursement level at least in the short term.

138. In 1998, McKesson tested the waters to see whether an increased WAC-to-AWP spread might help its relations with its retail customers. In March 1998, McKesson announced that it would begin utilization of First Data's AWP. McKesson and First Data knew – along with a few of the national chain drug retailers – that many of First Data's AWPs, and the timing of the reported AWPs, were often, albeit marginally, higher than other publications. While the stated purpose was to provide customers “with consistency in AWP pricing,” McKesson made clear to its retail pharmacy customers “that in almost every case retail prices will go up helping increase gross profit.” McKesson even instructed its retail customers regarding how to electronically

access the changed “markup percentages” to access increased gross profits earned at the expense of plan sponsors and consumers by shifting to First Data’s publication of AWP.

139. Following McKesson’s switch to exclusive use of First Data data, a handful of the largest national chain drug retailers continued to push for increased AWP/WAC markups on drugs, including increased WAC-to-AWP markups for branded drugs that were not already at the 25% level. In and around 1999, national chains and retailers requested increased AWP spread for branded products. Some of them engaged in practices to ensure that the increased markups would occur. For example, some large retailers refused to stock drugs that had therapeutic equivalent products if the product only had a 20% markup. Thus, these more powerful retailers could lock out the products unless the AWP/WAC spread was adjusted upward.

V. By 2001, First Data WAC-to-AWP Markups Were Susceptible to Abuse

140. By late 2001, the First Data editorial process for imputing the WAC/AWP markup factor for numerous NDCs of retail branded drugs was susceptible to manipulation by First Data and those with whom it worked, most notably McKesson. Although First Data held out to the public that its determination of the WAC/AWP markup factor was empirically driven through multiple sources, in truth there was no empiricism.

141. Many of First Data’s historical claims about its determination of the WAC/AWP markup were simply false. For example:

-- Although First Data claimed that because “individual wholesalers may markup each manufacturer differently, a weighted average, not a consensus average, is calculated”, in fact First Data never undertook weighted averages of reported markups. Thus, First Data’s publications over a decade had falsely claimed mathematical precision on empirical data for the markups.

-- Although First Data claimed that it undertook “surveys,” in fact no “surveys” in the reasonable sense of that word were undertaken. First Data’s questions were not set forth in a survey design, nor were they even in writing. Responses received were not memorialized in writing. No other paper trail was kept.

-- The purported "surveys" undertaken by First DataBank rarely occurred. When an inquiry was made, it was a monetary phone call lasting only a few moments.

-- Although First Data claimed, during the 1990s was "increasing" in fact the "surveys" were decreasing given the ongoing consolidation among national drug wholesalers. Moreover, First Data was not taking a calculated average of the markups reported, it only used a "consensus" approach which did not require a response from all the major national wholesalers.

-- During most times during the 1990s, even the wholesalers that were "surveyed" apparently did not know that they were being surveyed. Since the wholesalers themselves purchased their information about AWP from First Data itself, most found circular at best the notion that First Data would "survey" them to find out AWP information that the wholesalers themselves had already purchased from First Data.

-- By around 2000, only a few national wholesalers existed and were on the short list for First Data "surveys." Most of these wholesalers professed never to have participated in First Data "surveys" at any time. By the end of 2001, it appears that virtually all communications by wholesalers back to First Data regarding the WAC/AWP markup and/or AWP generally were expressly prohibited by management with the singular exception of McKesson.

142. First Data continued to mislead its customers and the public about the nature of its AWP and WAC-to-AWP markup data. For example, in a 2002 letter to subscribers of its publication Price Alert, First Data's Kay Morgan describes AWP as follows:

I have had many conversations regarding what "AWP" is and how First Data determines it. There is much folklore and misunderstanding as to the determination of AWP and how we obtain the data.

AWP is the average wholesale price. That is, AWP is the average of the prices charged by the national drug wholesalers for a given product (NDC), often referred to by First Data as the "Blue Book Price." The operative word is *average*. AWP was developed to provide a price, which all parties could agree upon.

In order to determine the AWP, First DataBank surveys national wholesalers to ascertain what the price is. This is based on their AWP price files. We contact the wholesalers to determine what the markup should be for a new company. ***First, DataBank then confirms that the markup is accurate and current.*** A survey may be performed on a single NDC number or on a manufacturer's entire product line. In either case, a survey will be performed with all national wholesalers to determine the appropriate AWP.

With increased numbers of surveys done, the determination represents over two-thirds of the volume of the wholesalers, and is also representative of wholesalers on a national level. Because individual wholesalers may mark up each manufacturer differently, a weighted average, not a consensus average, is calculated. That is, the market share held by the wholesalers surveyed affects the markup factor proportionally. Therefore, wholesalers with higher drug dollar volumes have more weight in the determination of the final markup. Thus, a higher degree of certainty is achieved. We also consider the manufacturer's suggested wholesaler price (SWP) in our determination. [Emphasis added.]

143. This 2002 publication, mimicking the similar 1991 First Data publication of eleven years earlier, maintained most of the falsehoods about First Data. On its 2002 website, First Data again claimed that its published AWP's result from *surveys* of national wholesalers and that the number of surveys was "increasing."

W. Implementation of the Five Percent Spread Scheme

144. On the eve of the McKesson and First Data Scheme, McKesson observed that: "[E]verything was straight forward for many years. Manufacturers' product lines were very consistent in their markups, and so were the FDB AWP's." This would soon change.

145. The genesis of the conspiracy to raise the WAC-to-AWP markup was FDB's desire to raise the markup or the AWP to "support our customers." MCKAWP 0068514. By "support" McKesson meant an increase in the margin earned by its retail clients. Thus, in September 2001, McKesson's Robert James reported in an internal e-mail (now marked "Highly Confidential" by McKesson) that McKesson chose to increase "the markup on the Park-Davis line (Lipitor) last January, when Pfizer took over. This was our attempt to raise AWP's to support our customers."

146. Shortly after his September 2001 e-mail, Robert James approached FDB to discuss FDB's willingness to "normalize the brand product AWP's." MCKAWP 0068599 (marked "Highly Confidential"). "Normalization" became one of the buzzwords used by

McKesson and FDB to describe their manipulation of the WAC-AWP spreads on hundreds of brand-name drugs.

147. As one of the largest national wholesalers, McKesson knew it had “an opportunity to ‘normalize’ AWP spreads on brand pharmaceuticals at a 25% markup (or 20% spread)” and, if it were to succeed, that “most [of its] customers would love it.” MCKAWP 0068514.

McKesson also knew it would not be difficult to impose its suggested sell prices on First Data’s published AWP’s because First Data’s “wholesaler surveys” consisted of nothing more than a brief phone call or e-mail. Initially McKesson merely changed its suggested sell price “in the hopes that one of the other wholesalers happens to raise their markup on an item (maybe due to pressure from retail customers), and FDB happens to resurvey the items.” MCKAWP 0068514. But when the competition did not respond as expected, or First Data failed to survey the change as quickly as hoped, McKesson decided to take direct action.

148. McKesson was aware that First Data had a virtual lock on the determination of AWP’s because it was one of only two electronic sources for price information. Although it was “not widely known,” McKesson knew that First Data had “a contract with the Medispan group [the only other electronic pricing source] requiring that FDB supply the data over the next 3 or 4 years [*i.e.*, through 2005 or 2006]. This means that essentially the Medispan data is the First DataBank data.”

149. In August 2001, despite McKesson’s knowledge that AWP’s were supposed to be the result of publishers’ surveys of actual wholesale prices, McKesson and FDB “mutually agreed” to move the AWP or WAC-to-AWP spread on all Searle products from 20% to 25%. Thereafter, McKesson and First Data agreed to implement a fundamental change in the WAC-to-AWP markups for branded drugs of all major manufacturers.

150. That defendant McKesson and First Data's collusion began as early as August 2001 is documented by an internal memorandum drafted by Bob James, McKesson's Director of Brand Pharmaceutical Production Management, stating:

After a discussion with FDB last August [2001], we mutually agreed to standardize Searle (16 $\frac{2}{3}$ % spread) product line because it had been acquired earlier by Pharmacia (20% spread). There seemed to be momentum in the industry to move to a normalized markup of 25% on brand Rx products. In December [2001], after several discussions with FDB about our [normalization] strategy we began to move many of the manufacturers with mixed spreads (16 $\frac{2}{3}$ and 20% products in the same line) to a consistent 25% markup. These were companies like GlaxoSmithKline,⁵ AstraZeneca, Aventis, Berlex, Bristol Myers Squibb, Merck, JOM, and 3M, Forest, Novartis, Roche, Schering and several others. These were mixed product lines and we just set their Suggested Sell Prices at a consistent 25% markup.

First DataBank re-surveyed most of these companies during January and February when price increases occurred. Many of the AWP's have been increased by FDB. Because a large number of price increases occurred, some AWP's were affected twice, once when the price increase[] took effect and then a second time when FDB raised the AWP after the survey process. . . . Not all products in these companies have had AWP increases at this point in time. However, as price increases occur FDB will re-survey those products and make their determination.

MCKAWP 69608-09.

151. Beginning sometime in late 2001 or early 2002, First Data and McKesson agreed to utilize for markup purposes data received solely from McKesson. At the same time and as part of a common plan, McKesson implemented a 5%⁶ increase in the WAC-to-AWP markup for hundreds of brand-name drugs that it distributed. This increase was from 20% above WAC to 25% above WAC for the affected drugs. As part of their price-fixing agreement, and their agreed-upon course of conduct and common plan, First Data then published new figures for hundreds of brand-name drugs without contacting any other wholesaler. First Data continued to

⁵ GlaxoSmithKline ("GSK") wrote on March 1, 2002 to First Data asking it to explain the "unexpected change" which led First Data to list GSK products with a 25% markup. FDB-AWP 053695.

⁶ Sometimes the increase was more than 5%, as the intent was to raise all markups to 25%. So if a drug was at 18%, it was moved up to 25%.

publicly state that it contacted more than one wholesaler to obtain a “weighted average.” First Data knew that this across-the-board increase from 20% to 25% was not due to any real economic change in the average wholesale price, and that by publishing this increase, it was not providing “reliable” and “accurate” information as it had promised. McKesson for its part knew that the 5% increase was not justified by any change in the price of drugs or other change in the marketplace. Rather, McKesson implemented this 5% increase solely to benefit its own pharmaceutical business and the business of its prominent retail pharmacy clients.

152. By November 2001, FDB’s Kay Morgan, and McKesson’s Robert James, were exchanging e-mails confirming the results of their collaboration: “Hello Kay.... Just went through the Merck items and updated a couple of our items to 25% markup. However, found some items that you might want to review. They include Noroxin’s Prinvil and Prinzides. The latter two should probably be consistent with the new AZ 1.5 markups.” MCKAWP 0068621 (“Highly Confidential”).

153. McKesson’s own internal documents describe the profitability of increasing spreads for its key customers. Thus, McKesson noted the following:

Here are a few examples of increased profits that our customers should be realizing now and into the future. The following results are based on a reimbursement formula of AWP minus 15% plus a \$2.00 fee.

	Old 16 2/3% spread	New 20% spread
Lipitor 20mg 90’s	\$6.86	\$17.18
Prilosec 20mg 30’s	\$4.22	\$8.92
Allegra 60mg 100’s	\$3.97	\$8.16
Advair Diskus 500/50 60dose	\$5.11	\$11.70
Befaseron (previously a flat \$7.00 fee)	\$20.00	\$58.25

Most would agree that these improvements are extremely significant.

154. In December 2001, FDB and McKesson engaged in “discussions” that resulted in an increase in the markups of companies “like GlaxoSmithKline, AstraZeneca, Aventis, Berlex, Bristol Myers Squibb, Merck, JOM, and 3M, Forest, Novartis, Roche, Schering and several others.” MCKAWP 0069608.

155. McKesson’s collaboration with First Data was highly effective. In March 2002, Robert James reports:

My guess is that things should look very good in the next couple of months. I am working with FDB to point out problem suppliers as Erlinda’s group [Business Information Services] provides me with weekly information comparing our List price with the FDB AWP. . . . [The] results should have a very positive impact on our customers[’] profitability.



MCKAWP 0042663. In April he reports that First Data gave up all pretense of conducting a survey for new products: “All new brand vendors will be set up as 1.25 markup factor vendors, both at McK and FDB.” MCKAWP 0069616.

156. An increase in the WAC-to-AWP spread directly results in higher prices to Plaintiff State of Connecticut. For example, in the case of AstraZeneca’s Prilosec (as reflected in the chart below), the AWP spread increase raised the AWP for that drug by \$295.72. The following chart reflects, for a single drug manufactured by certain companies, the AWP spread increase and related AWP increase:


Manufacturer	Drug	AWP Before 2000	WAC Before 2000	AWP Spread Before 2000	AWP After 2000	WAC After 2000	AWP Spread After 2000
Abbott	Biaxin 500 mg #60	\$396.72	\$334.08	18.8%	\$437.98	\$350.38	25%
AstraZeneca	Prilosec 40 mg #1000	\$6,171.66	\$5,143.05	20%	\$6,621.67	\$5,297.34	25%
Aventis	Allegra 60 mg #100	\$118.36	\$98.63	20%	\$123.29	\$98.63	25%
BMS	Tequin 400 mg #100	\$818.86	\$682.27	20%	\$895.48	\$716.38	25%
GSK	Combivir #100	\$1,241.26	\$1,034.38	20%	\$1,370.55	\$1,096.44	25%
J&J (Janssen)	Risperdal 2 mg #500	\$2,320.10	\$1,933.42	20%	\$2,535.20	\$2,028.16	25%
Novartis	Exelon 2 mg/ml	\$246.96	\$205.80	20%	\$267.29	\$213.83	25%

157. Another way to understand the widespread nature of the change in the WAC-to-AWP markup as a result of the McKesson-First Data agreement is to examine the change in the WAC-to-AWP markup of all drugs manufactured by the following illustrative pharmaceutical manufacturers over time: The increases, all occurring in hundreds of drugs, among multiple manufacturers, at the same time, could not have happened by chance or independent conduct, but instead are the result of a common plan.


Number of NDCs Experiencing a WAC/AWP Spread Change from 20% to 25%






GLAXOSMITHKLINE
Number of NDCs with Spread Change from 20-25%, 1999 - 2004




BRISTOL-MYERS SQUIBB
Number of NDCs with Spread Change from 20-25%, 1999 - 2004







158. Examining the scheme on an annual basis also illustrates the timing and extent of the scheme's implementation:



159. The dramatic across-the-board increase in the spread on hundreds of brand-name drugs was implemented pursuant to the joint scheme between McKesson and First Data. As noted, McKesson reported the WAC-to-AWP increase to First Data, and First Data in turn agreed to report the new AWP.

160. First Data was aware that the markups McKesson reported were inflated to improve relations with McKesson's customers – the pharmacies – by increasing their profits. Around August 2001, McKesson discussed this with First DataBank. Moreover, in February 2002, Bob James sent Kay Morgan a document he drafted entitled, "AWP Discussion," explaining that 20% markups "had a negative impact on McKesson's customers' profitability," and that "McKesson has chosen to 'normalize' the markups in the Brand Rx area resulting in a consistent 25% markup or use of the 1.25 factor." MCKAWP 0069613. Later, on May 1, 2002, Bob James wrote to Kay Morgan about the "normalizing process," the term McKesson coined to refer to its efforts to impose a uniform 25% markup on all brand prescription drugs. MCKAWP 0069642. In an July 2002 e-mail sent to Alicia Nielson, First Data's Senior Research Associate, Product Knowledge Base Services, Bob James enclosed a prior internal communication in which he explained that McKesson had "been normalizing all Brand Rx mark ups at 25% for the suggested sell price." MCKAWP 0069775. First Data enthusiastically embraced the "normalization" program, as reported in the following Aventis March 11, 2002 e-mail from Guerdon Green, Director of Trade Administration & Development at Aventis:

First Data Bank has advised me after surveying the wholesalers, they feel that there are very few manufacturers that still have a 20% AWP to WAC spread [sic, markup]. As a result, First Data Bank has determined to employ a higher 25% AWP to WAC [markup] for all Aventis products. This will be implemented as we have price increases. Immediately the entire Allegra line will be moved to a 25% [markup] from its current 20%. This will be effective immediately. The most noticeable impact will be that it will be more profitable to the retail pharmacist to dispense Allegra.

161. Eventually First Data ceased consulting with any other wholesalers and relied entirely on the information that McKesson provided it to determine AWP's. McKesson was aware that First Data routinely disregarded manufacturer's suggested sell prices – Kay Morgan frequently shared such snubs with her friend Bob James:

Let's start a list of the hated manufacturers, we will update it weekly or monthly. Today, Organon is the top of my list. The person in charge of EDI is trying to tell me to put O in the first position. McKesson and we have it wrong. Wound up telling her that the world does not turn around Organon and sending a note to my contact telling him the product was coming off.

MCKAWP 0069586.

* * * * *

[in response to an e-mail from Gilead Sciences announcing that it would not longer report AWP's for its products and requesting that any publication of an AWP calculated by First Data be accompanied with the statement that the price was not authorized by Gilead, Kay Morgan writes:] Wonderful. If we don't report an AWP, the NDC will not be listed. It is the rules of the database. . . .

[to Bob James] FYI –Just thought you should be aware. They appear to be playing hardball and I just don't play.

MCKAWP 0001183.


162. Before 2000 McKesson estimated that only 20% of the prescription drug manufacturers were 25% mark-up companies. MCKAWP 0069502. By early 2002, however, McKesson estimated that, through its efforts, 90% of the industry had turned to the 25% markup. MCKAWP 0069609. By late 2002, McKesson estimated that the number had increased to 95%. MCKAWP 0069502. In 2004, McKesson estimated that 99% of the prescription drugs were set at a 25% markup. MCKAWP 0069766. McKesson acknowledged that without its efforts, “the AWP's most likely would not change,” MCKAWP 0069732, and that the industry shift “probably speaks to First Data Bank's willingness to work with us to normalize the brand product AWP's.” MCKAWP 0068599.

X. McKesson's Purpose in Implementing the Scheme was to Curry Favor With Retailers and Gain a Competitive Advantage Over Other Wholesalers

163. McKesson had a motive to implement this Scheme. Pharmacies are reimbursed for drugs by health plans and other pharmacy benefit providers based on AWP. Consequently, pharmacies make a profit on the spread between AWP and the actual acquisition cost for the drug. Under this system, a higher WAC/AWP spread results in increased profits to pharmacies. Thus, McKesson and First Data, by operation of the scheme, benefited retail pharmacies. The scheme also benefited PBMs (Pharmacy Benefit Managers), particularly those who operate by mail order, by allowing them to make increased profit off the spread. As set forth below McKesson's major client base on many levels of its business are retail pharmacies. The scheme was highly beneficial to such clients and as outlined below pleasing these clients was a major objective, that McKesson believed would provide it with an advantage over its competitors.

Y. McKesson/First Data Collaborate to Hide the Scheme

164. McKesson and First Data also agreed to hide the price-fixing scheme by implementing the WAC-to-AWP increases only when the manufacturer increased WAC. McKesson and First Data were fearful to implement the scheme without such an increase because such action "would trigger a lot of questions on why there was a change to the item when the MFG (manufacturer) hasn't sent any price changes." To avoid having End Payors ask questions, McKesson and First Data camouflaged the scheme by imposing the 5% increase when other price changes were reported, thus in effect compounding price increases. This part of the scheme is depicted by the following chart showing a dramatic increase in the number of 25% spreads associated with price changes in 2002 and 2003:



165. After the scheme was implemented, and despite the flack from some drug manufacturers, First Data and McKesson continued their collaboration to ensure that First Data’s WAC/AWP markups mimicked those of McKesson, and vice-versa. In their efforts to effectuate the scheme, McKesson conducted weekly comparisons of its list prices and First DataBank’s published AWP’s. Moreover, McKesson and FDB regularly communicated to “point out the problem suppliers.” MCKAWP 0042663.

166. These post-2001 communications were in no sense a First Data “survey.” Indeed, the communications were bilateral, with First Data equally enforcing the new WAC/AWP markup protocol. And even when disparities arose in the databases, First Data would counsel against making changes because “it would trigger a lot of questions on why there was a change to the item when the MFG [*i.e.*, manufacturer] hasn’t sent any price changes.”

167. At times, when McKesson was “catching some flack from our large retail friends,” McKesson would ensure that both it and First Data’s databases contained the higher WAC/AWP markup. At other times, a large national chain pharmacy would call “complaining

about” the particular AWP for a product, and McKesson, in turn, would contact First Data in order to get it “fixed.”

168. McKesson sought to hide the scheme. When Brian Ferreira of VPS Retail wrote to Bob James, asking him to “[p]lease provide the list of items and/or manufacturers that were included in the AWP standardization process,” James knew better than to respond to the request in writing, instead responding: “Brian, this is an interesting request. . . . Please give me a call when it is convenient.” MCKAWP 0069714. McKesson knew that if it did not keep its manipulations of the AWPs a secret, there would be serious repercussions:

Confidentially. Not to pass on. We have [only] about 470 brand Rx items

* * * * *

[John Bonner, Director, McKesson’s Branded Rx Product Management and Investment] Bob James is working with FDB to make this happen over time and I’m not sure it is something we want discussed. Please contact him before discussing outside the company.

MCKAWP 0066465.

[Bob James] For obvious reasons we don’t want to write a memo and send it out because it would not be kept confidential.

MCKAWP 0069591.

[Bob James to McKesson field associate] I would be careful about ‘being ahead of the curve with Lilly. You be the judge on how your customer will interpret.

MCKAWP 0069594.

[McKesson field associate writing to John Bonner] My accounts are having issues with us ‘Normalizing brand pricing at 25%’ You also mentioned that we should not discuss [this] outside of McKesson, how would you suggest we answer our customers[?] questions?

MCKAWP 0066464.

[McKesson field associate] Obviously this is not out to the field.

MCKAWP 0069732.

[Bob James] Sorry for the extra confusion and questions that have come up from our customers. The (unintended consequences) results [of the normalization process] should have a very positive impact on our customers['] profitability.

MCKAWP 0042663.

169. First Data also knew the importance of keeping the scheme a secret. In response to an e-mail inquiry regarding whether electronic drug pricing publishers were increasing the AWP/WAC spread, Kay Morgan denied any involvement, adding, "I am most curious as to the source of this rumor. First Data has always used a wholesaler survey to determine AWP."

MCKAWP 0069588. She forwarded on the exchange to Bob James at McKesson, stating, "I thought you might want to see my answer," to which he responds: "I love it! You are the best."
Id.

170. When in 2003 one manufacturer indicated that it would "no longer report average wholesale prices (AWP) for its products", First Data reported to McKesson that this manufacturer appeared "to be playing hard ball and [First Data] just won't play." First Data indicated that it would, then, "just assume the markup is 1.25." In this situation, when the manufacturer wanted to be assured that any disclosure of an AWP associated with its product was a price that "has not been authorized" by it, First Data wrote back stating: "Wonderful. If we don't report an AWP, the NDC will not be listed. It is the rules of the database. That database does not allow for statements such as your attorneys wrote below." MCKAWP 0001183.

171. First Data's participation in the scheme is also evidenced, in part, by its conduct with respect to AWP's reported to First Data from certain manufacturers. For example, in *In re Pharm. Indus. Average Wholesale Pricing Litig.*, MDL No. 1456 (D. Mass.), Novartis filed

declarations stating that Novartis regularly communicated its AWP to the publishers, including First Data and that for the period March 27, 2000 through August 21, 2002, the AWP published for its drugs was 20% higher than the WAC Novartis reported. Novartis then stated in its declaration that, since January 18, 2002, First Data consistently published an AWP that was 5% higher than the AWP reported by Novartis, or 25% over WAC. The Novartis declaration, however, did not describe anything Novartis had done to remedy First Data's fraudulent reporting of Novartis' AWP.

Z. Some Branded Manufacturers' Response to the McKesson/First Data Scheme

172. Some branded manufacturers noticed implementation of the scheme and immediately appreciated its purpose – to provide additional profit to the wholesalers and retailers in the pharmacy class of trade. One branded company commented that “First Data, at the direction of the wholesale industry, has begun to change all branded pharmaceutical products to a 25 % markup” and that “the spread will be changed as product price changed[.]” The same company observed that the “largest negative factor is publicity” since the increase in AWP would increase End Payors' prices.

173. A different branded manufacturer also observed that the changed WAC/AWP markup for many branded drugs was “being driven at wholesaler level” and that they are “reporting 1.25 when companies take a price increase. . . .”

174. Because branded and generic manufacturers have historically established AWP's for their NDCs either directly (by suggesting an AWP that was incorporated by First Data and wholesalers) or indirectly (by setting a WAC and setting or knowing of the markup factor to be applied to that WAC), manufacturers whose NDCs had been affected by the McKesson/First Data Scheme asked First Data for answers as to why the markups had changed for selected branded products in 2002. In response, First Data generally pushed them off, giving different

answers to different manufacturers. To make matters worse, First Data had counsel for its parent, the Hearst Corporation, write letters to various branded manufacturers' representatives. In these letters, Hearst's lawyers made claims which were false.

175. Ultimately, brand-name manufacturers acquiesced to the results of the McKesson/First Data Scheme. Moreover, branded manufacturers took no action to disclose the existence of the inflated AWP which had been effectuated by the scheme to change the WAC/AWP markup. As a result, while First Data and McKesson as insiders to the scheme were well aware of the changed markup factor (and corresponding increase in reimbursement payments being made throughout the country), and while some branded manufacturers were similarly aware that many of their branded products had experienced the WAC/AWP markup change without their explicit request, none of them disclosed this to the marketplace at large. Indeed, some manufacturers republished or utilized the new First Data AWP in communications to customers or other publishers. In a market where billions of prescriptions are filled each year, where over 65,000 NDCs are actively in the marketplace, and where the WAC/AWP Scheme was sequentially implemented during the course of 2002 and later as price increases imposed by the manufacturers were effectuated, the scheme went unnoticed to the marketplace at large. Indeed, even when players in the pharmaceutical marketplace noticed the increases in the WAC/AWP spread, they assumed by virtue of the manufacturers' silence that those increases were the result of the actions of those manufacturers.

AA. First Data's March 2005 Announcement

176. Then, in a March 15, 2005 letter, First Data announced that the unreliable surveys would be discontinued. Reviewing its past practices with respect to establishing AWP, First Data restated that it had conducted surveys to establish AWP:

March 15, 2005

Re: First DataBank's Blue Book AWP Data

Dear Customer:

It is our pleasure to serve you as a customer of First DataBank. We are writing to make you aware of upcoming changes to First DataBank's National Drug Data File Plus™ database, or NDDF Plus™, that may impact your use of our products.

In order to publish various drug pricing data fields available through its NDDF Plus database and related products, *First DataBank has historically relied on drug manufacturers and wholesalers to report or otherwise make available information concerning their list price for drugs.* Unfortunately, First DataBank is no longer able to obtain information relating to list prices directly from wholesalers in a manner that is consistent with First DataBank's editorial standards and policies. In fact, it is our understanding that some wholesalers often do not use catalog or list prices as a basis for determining actual transaction prices. As a result, First DataBank must implement certain changes to its publication of the "Blue Book AWP" pricing data field. Effective immediately, First DataBank will no longer survey drug wholesalers for information relating to their catalog or list prices.

First DataBank historically relied upon wholesalers to provide information relating to their catalog or list prices for purposes of publishing the Blue Book AWP data field. *First DataBank periodically surveyed full-line national wholesalers to determine the average markup applied to a manufacturer's line of products. The average markup of the wholesalers responding to the survey was applied against the Wholesale Acquisition Cost (the manufacturer's list price to wholesalers, also commonly referred to as WAC) or, if a Wholesale Acquisition Cost was not available, the Direct Price (the manufacturer's list price to non-wholesalers), with the resulting value populating the Blue Book AWP field. In certain instances, wholesalers would accept a manufacturer's suggested wholesale price, in which case the Blue Book AWP and Suggested Wholesale Price data fields would reflect the same value. [Emphasis added.]*

BB. Fraudulent Concealment

177. The conspirators cleverly hid their conduct behind FDB's confidential survey process to avoid detection and to preserve for as long as possible the benefit they had conferred to the pharmacies. FDB continued to make false or misleading statements about the integrity of

its data and the means by which it calculated its AWP.⁷ FDB also kept McKesson's participation in the process secret by refusing to disclose the alleged survey results on alleged grounds of confidentiality. Additionally, both McKesson and FDB either denied, or failed to disclose to the public, their common plan of "normalizing" WAC/AWP markups at 25% and their respective roles in achieving this goal.⁸ Communications between McKesson and FDB, and internal McKesson communications about FDB, over a three-year period indicate that they fraudulently concealed the 5% Scheme. McKesson voluntarily provided FDB drug pricing information, including WACs, AWP and WAC/AWP markup information.⁹ McKesson and FDB regularly communicated and shared drug pricing information, usually by telephone and e-mail, including discussions, in which they agreed to the markup factor for a manufacturer or brand-drug line.¹⁰

178. Plaintiff had no knowledge of the combination and conspiracy alleged herein or of any of the facts that might have led to the discovery thereof in the exercise of reasonable diligence prior to the filing of a complaint in U.S. District Court in Boston alleging the scheme in December 2005.

179. Plaintiff could not have discovered the existence of the combination and conspiracy alleged herein at an earlier date by the exercise of reasonable due diligence because of the deceptive practices and secrecy employed by McKesson, and its co-conspirator First

⁷ For example, FDB-AWP 02005 (page from FDB's website, dated November 4, 2002) (stating that FDB surveys each of the national wholesalers to determine markup), which Kay Morgan acknowledged was never a true statement of FDB's survey practice. Patricia Kay Morgan 6.28.07 Dep. at 100:16-23.

⁸ For example, Kay Morgan forwarded an e-mail to Bob James, in which she is directly questioned about whether FDB is moving all manufacturers to a uniform 25% markup. Morgan categorically denies the Scheme. James' response is: "I love it. You are the best!" MCKAWP 0069588.

⁹ Both FDB employees charged with maintaining the integrity of the drug pricing data at FDB testified that McKesson regularly provided markup information. Morgan 6.28.07 Dep. at 89:17-90:11; Alisha Nielson 5.18.07 Dep. at 97:16-19.

¹⁰ For example, MCKAWP 0068621; MCKAWP 0069586; MCKAWP 0069857; MCKAWP 0001168; and MCKAWP 0001188.

DataBank to avoid detection and their affirmative concealment of such violations, including without limitation, falsely attributing markup increases to the wholesaler industry as a whole, as opposed to McKesson's secret normalization agenda. Additionally, when asked directly whether First DataBank was in the process of normalizing markups, First DataBank not only denied this and demanded to know the source of this "rumor," but forwarded its response to McKesson's Bob James, who responded: "I love it! You're the best." Similarly, in a conference call with Aetna, McKesson denied that it had any control over rising AWP's, while at the same time it bragged to select customers that McKesson had "done its part" to increase AWP's through increased markups. Moreover, First DataBank refused requests to disclose the responses to its so-called surveys, claiming confidentiality in the process. Nor did McKesson publicly reveal its normalization scheme, knowing that if the increases were revealed, managed care would renegotiate with retail pharmacies and McKesson's "gift" to retailers would be lost.

180. As a result of the active fraudulent concealment of the conspiracy, Plaintiff asserts the tolling of the applicable statute of limitations affecting the causes of action by Plaintiff.

V. CLAIMS FOR RELIEF

FIRST COUNT

CIVIL RICO (18 U.S.C. § 1962(c))

181. Plaintiff incorporates by reference all preceding paragraphs as if fully set forth herein and further alleges as follows.

182. Plaintiff and the defendant are each "persons," as that term is defined in 18 U.S.C. § 1961(3).

183. At all relevant times, in violation of 18 U.S.C. § 1962(c), the defendant along with its co-conspirator, First DataBank (collectively "the co-conspirators"), conducted the affairs

of certain association-in-fact enterprises identified herein, the affairs of which affected interstate commerce through a pattern of racketeering activity.

A. The McKesson-First Data Enterprise

184. For purposes of this claim, certain RICO “enterprises” are associations-in-fact within the meaning of 18 U.S.C. § 1961(4), consisting of (a) First Data and (b) McKesson, including their directors, employees and agents. These associations-in-fact are sometimes collectively referred to herein as the “McKesson-First Data Enterprise.” The Enterprise is an ongoing and continuing business organization consisting of both corporations and individuals that are and have been associated for the common or shared purposes of (a) publishing or otherwise disseminating pharmaceutical price information, which all too often includes disseminating false and misleading AWP; (b) implementing the 5% Spread Scheme; (c) deriving increased profits from the activities of the Enterprise; and (d) perpetuating the use of AWP as a benchmark for reimbursement in the pharmaceutical industry. First Data and McKesson each had a common purpose of perpetuating the use of AWP as a benchmark for reimbursement in the pharmaceutical industry and a common purpose in inflating the AWP by 5%.

185. The Enterprise has a systemic linkage because there are contractual relationships, financial ties, and continuing coordination of activities between McKesson and First Data. There is a common communication network by which McKesson and First Data shared and continued to share information on a regular basis throughout the time period including August 1, 2001 through the present. Typically this communication occurred by use of the wires and mails in which McKesson and First Data discuss and agree on the new WAC-AWP spread for a given drug. McKesson and First Data functioned as a continuing unit for the purposes of implementing

the 5% Scheme. When issues arose during the Scheme each agreed to take actions to hide the scheme and to continue its existence.

186. At all relevant times, First Data was aware of McKesson's conduct; was a knowing and willing participant in that conduct; and reaped profits from that conduct. First Data was aware that its published AWP's were inflated by the 5% Scheme. This awareness comes from the following sources: First, prior to the Scheme, First Data had in some instances obtained markups from wholesalers, which made First Data aware, even absent its agreement with McKesson, that its reported AWP's were not accurate. Second, as various congressional bodies and government agencies reported on AWP inflation, First Data did not change or challenge manufacturers regarding the self-reported WAC and AWP's, or the markups that First Data used. Third, First Data stopped conducting even limited surveys of other wholesalers and simply accepted the 5% Scheme, when it knew there was no basis for this 5% bump. Fourth, First Data actually received letters from certain manufacturers stating that the 5% increase in AWP was not justified. McKesson and First Data initiated the 5% Scheme in 2001-2002 and continued the scheme in force in 2003-2004. Finally, McKesson and First Data regularly discussed the scheme in wires, e-mails and in telephone conversations.

187. The scheme went to the point where FDB would query McKesson whether there had been a WAC increase so that a given drug could go to a 25% markup. Thus, both McKesson and FDB conspired to implement the scheme. MCKAWP 0069553.

188. The scheme evolved to such an extent that McKesson would send to FDB, via e-mails, a "screen print" to indicate that the "WAC, markup and suggested sell price," always showed a 25% markup.

189. The impacts of the scheme are still in place, *i.e.*, the increased spreads are still being maintained. As described earlier, for sales to non-cash paying customers, pharmacies are reimbursed by health plans and other pharmacy benefit providers based on AWP. Consequently, pharmacies make a profit on their spread between AWP and the actual acquisition cost for the drug. Under this system, a higher WAC-to-AWP spread results in increased profits to pharmacies. Thus, McKesson and First Data helped deliver greater profits to pharmacies by conspiring to increase AWP's. McKesson has admitted that its conduct caused an increase in the AWP's that are used to price brand-name drugs. McKesson's expert Joseph Kalt, in a January 28, 2008 report, admitted that "McKesson's higher SSPs ("suggested sales prices") led to higher AWP's published by FDB." Kalt Report at 16.

190. This was acknowledged in McKesson's internal mails, where McKesson's executives discussed the positive impact of "normalizing" on McKesson's customers:

Here is an idea. Two years later, ***and having had some recent success in raising AWP's***, I think this could be presented to him positively in this way.

Omnicare is looking for say \$500,000 in benefit from year end deals, even though this was not part of their contract. We need to ask them to roll up ***or recalculate their reimbursements for last year based on the new AWP's with a 20% spread***. And.....this is not just a one time benefit. ***They will receive this now and each year going forward until they renegotiate contracts with third parties (and hopefully do not give up this gift)***.

Our successes recently and during this past year includes raising AWP spreads to 20% (markup of 25%) include Parke Davis (division of Pfizer). Searle (division of Pharmacia). GlaxoSmithKline (Glaxo was at 16 2/3%). AstraZeneca, TAP, Berlex, JOM including Alza and Centocor, parts of Merck and BMS where things were mixed between 16 2/3% and 20%, and more to come. Some of our friends in retail that I have spoken with are pretty overwhelmed that we would be "driving" this process on their behalf. Of course, we are not solely responsible for this "normalizing" of AWP's but we have done our part as I have discusses with your previously. I have had conversations with Albertsons and Safeway and a few others.

Remember, “McKesson is doing this to improve our efficiencies in our BIS group.” With mixed AWP spreads, our BIS group is required to make manual overrides (for every pricing activity) to input the First Data Bank AWP whenever there is a difference from our Suggested Sell or List Price. It could be stated as a benefit of the Sixth Sigma method of identifying defects. An “unintended consequence” is that the profitability of our customers will be impacted in a appositive way. ***They will basically get 3 1/3% more profit on Rx’s filled with this new AWP spread. (Just imagine what this would mean on drugs like Lipitor or Prilosec....***

This strategy might be of interest to Jack Fragie, Larry Greco, and others in discussions with our large national accounts, prospective new customers, and buying groups like Servall and IPC (that are continually asking for lower costs, more added value, and discounts beyond their contract language.....like Owens programs). ***We have an opportunity to “market” our efforts now.*** If we do not do this, its possible that some of these accounts will believe that this stuff just happens and the efforts will go unrecognized. In my discussions, one of the comments that was made was “this would certainly be a good reason to renew our agreement with McKesson when its time.” Talk about being good partners, wow! This is worth further discussion as we go forward. Maybe, a proactive strategy like this will soften some of the activity around asking for lower costs and more benefit.

MCKAWP 0065895 (emphasis added).

191. Nonetheless McKesson also realized that it could “‘market’ [its] efforts” by informing its customers that it was “doing everything possible to ‘raise’ AWP’s when appropriate.” MCKAWP 0065895. McKesson appreciated that if it failed to inform its customers that it was behind all these changes “it’s possible that some of these accounts will believe that this stuff just happens and our efforts will go unrecognized.” MCKAWP 0065895. As one McKesson executive put it: “This sounds like something we should at least [be] quietly communicating to our customers in order to get some mileage from it[.]” MCKAWP 0069732.

And so it began:

[To Dan Connolly of Bartell Drugs]: Celexa and Lexapro will have an AWP markup of 25% or a spread of 20% as soon as FDB information is updated. Look for the change to happen next week. Keep smilin[g] . . . and who said we never listen to our customers (and old friends).

MCKAWP 0069817.

[To Dan Connolly]: Just wanted you to know that Clarinex AWP spreads went to 20% this week. A few weeks ago Celxa went to 20% as well. Fat cat status is just around the corner.

MCKAWP 0069901.

[To David Vucurevich of Rite Aid]: P.S. latest AWP changes . . . Celxa and Clarinex, working on Lilly and Novo.

MCKAWP 0069911.

192. A field agent reports: “Some of the more savvy stores like Med-X have taken notice.” MCKAWP 0069732. Bob James realized that the goodwill McKesson established with the pharmacies as a result of inflating AWP’s would give it a substantial edge over its competition:

In my discussions [with select customers about McKesson’s efforts to “normalize” the AWP markup at 25%], one of the comments that was made was “this would certainly be a good reason to renew our agreement with McKesson when its time.” Talk about being good partners, wow! This is worth further discussion as we go forward. Maybe a proactive strategy like this will soften some of the activity around asking for lower costs and more benefit.

MCKAWP 0065895.

193. Bob James proposed disclosing McKesson’s efforts to customer Omnicare who purportedly was looking for an extra-contractual year-end bonus in the neighborhood of \$500,000:

Omnicare is looking for say \$500,000 in benefit from year end deals, even though this was not part of their contract. We need to ask them to roll up or recalculate their reimbursements for last year based on the new AWP’s with a 20% spread. And this is **not just a one time benefit**. They will receive this now and for each year going forward until they renegotiate their contracts with third parties (and hopefully do not give up this gift).

MCKAWP 0065895 (emphasis, ellipses in original). Bob James also noted with pleasure that Kay Morgan spoke “with Eric Sorkin at RiteAid to let him know how much effort we are putting

into this AWP thing to get it right.” MCKAWP 0069669. Other customers were also appreciative. For example an unnamed customer from Ohio, called McKesson “to say that he was looking at some of these items again and found that the spread appears to have increased significantly on most of these items to the area of 20-21%. He wondered if we had any part in doing this and, if so, he wanted to let us know that he really appreciated our efforts.” MCKAWP 0069513. Med-X Corp.’s Director of Operations, Jerry Howard reviewed the numbers, put two and two together, MCKAWP 0069732, and “was very ex[c]ited about” McKesson “working on AWP expansion.” MCKAWP 0069726.

194. The foregoing shows that First Data and McKesson each was a willing participant in the McKesson-First Data Enterprise; had a common purpose and interest in the establishment and operations of the scheme; and their agreement to a structure wherein First Data and McKesson agreed on how the operation of the McKesson-First Data Enterprise would be conducted, *i.e.*, through McKesson’s transmission of increased markups and First Data’s publication of those markups. This structure was the basis in which the McKesson-First Data Enterprise operated.

B. The Defendant’s Use of the U.S. Mails and Interstate Wire Facilities

195. The McKesson-First Data Enterprise engaged in and affected interstate commerce because it engaged in the following activities across state boundaries: The transmission and publication of false and misleading information concerning AWP.

196. During the time period including August 1, 2001 through the present, the defendant’s illegal conduct and wrongful practices were carried out by an array of employees, working across state boundaries, who necessarily relied upon frequent transfers of documents and information, products and funds by the U.S. mails and interstate wire facilities.

197. The nature and pervasiveness of the scheme, which was orchestrated out of the corporate headquarters of defendant McKesson and First Data, necessarily required those headquarters to communicate directly and frequently by the U.S. mails and by interstate wire facilities.

198. Many of the precise dates of defendant and First DataBank's uses of the U.S. mails and interstate wire facilities (and corresponding RICO predicate acts of mail and wire fraud) have been hidden and cannot be alleged without access to their books and records. Indeed, an essential part of the successful operation of the scheme alleged herein depended upon secrecy, however, Plaintiff can generally describe the occasions on which the RICO predicate acts of mail fraud and wire fraud occurred, and how those acts were in furtherance of the scheme. Plaintiff describes this as follows:

199. The defendant and First DataBank's use of the U.S. mails and interstate wire facilities to perpetrate the 5% Scheme involved thousands of communications throughout the time period including August 1, 2001 through the present, including, *inter alia*:

(a) Marketing materials about First Data's services, which First Data, sent to health care providers located across the country;

(b) Written representations and telephone calls between McKesson and First Data regarding markups and AWP's, which occurred on a regular basis each year;

(c) Hundreds of e-mails between McKesson and First Data agreeing to, or effectuating the implementation of, the scheme. These e-mails included, but are not limited to, the emails identified earlier in this Complaint;

(d) Written and oral communications directed to U.S. Government agencies and private insurers that fraudulently misrepresented what the AWP's were, or that were intended

to deter investigations into the true nature of the AWP's or to forestall changes to reimbursement based on something other than AWP's;

(e) Receipts of increased profits – the wrongful proceeds of the scheme – sent through the U.S. mails and interstate wire facilities; and

(f) In addition to the above-referenced RICO predicate acts, it was foreseeable to defendant that First Data would distribute publications containing false AWP's through the U.S. mails and by interstate wire facilities. Further, defendant has, in furtherance of the scheme, communicated through use of the U.S. mails and by interstate wire facilities with their various local headquarters or divisions. These uses of the U.S. mails include some of the documents referenced in this Complaint.

200. Defendant's pattern of racketeering activity includes acts indictable as mail fraud under 18 U.S.C. § 1341 and wire fraud under 18 U.S.C. § 1343. Defendant's fraudulent scheme consisted of, *inter alia*: deliberately causing falsely inflated AWP's to be published or disseminated so that Plaintiff and other End Payors would pay excess charges for the drugs that are the subject of this lawsuit.

C. Conduct of the RICO Enterprises' Affairs

201. The defendant has exerted control over the Enterprise and, in violation of Section 1962(c) of RICO, the defendant has conducted or participated in the conduct of the affairs of those RICO enterprises, directly or indirectly, in the following ways:

(a) Both McKesson and First Data had a degree of control concerning the WAC-to-AWP spread and each had AWP's that First Data reported;

(b) First Data has directly controlled the creation and distribution of marketing, sales, and other materials used to inform members of the Class as to the value of its services;

(c) McKesson intended that First Data would (and did) distribute their publications containing false AWP's through the U.S. mails and by interstate wire facilities; and

(d) First Data allowed defendant McKesson to exert control over its organization, knowing that the AWP's were inflated as a result of the 5% Scheme and were not real numbers. McKesson controlled First Data by virtue of its ability to cause an increase in the WAC-AWP markup. First Data did so because the reporting of AWP's was, and is, a major part of its business, and McKesson was integral to First Data's AWP reporting and to increasing First Data's profits for the reasons set forth herein.

202. The McKesson-First Data Enterprise had a hierarchical decision-making structure headed by McKesson. McKesson issued instructions on how the WAC-to-AWP spread was to be reported and each Publisher accepted those instructions despite knowing of their falsity.

203. In violation of Section 1962(c) of RICO, defendant conducted the affairs of the McKesson-First Data Enterprise with which it associated by establishing a phony extra 5% WAC-to-AWP spread that First Data then published and disseminated nationwide.

D. The Pattern of Racketeering Activity

204. Both defendant McKesson and its co-conspirator, First Data, conducted and participated in the affairs of the above-referenced Enterprises through a pattern of racketeering activity, including acts that are indictable under 18 U.S.C. § 1341, relating to mail fraud, and 18 U.S.C. § 1343, relating to wire fraud. This pattern of racketeering likely involved thousands of separate instances of use of the U.S. mails or interstate wire facilities in furtherance of their scheme. Each of these fraudulent mailings and interstate wire transmissions constitutes a "racketeering activity" within the meaning of 18 U.S.C. § 1961(1)(B). Collectively, these violations constitute a "pattern of racketeering activity," within the meaning of 18 U.S.C.

§ 1961(5), in which the defendant intended to defraud Plaintiff, members of the Class and other intended victims.

205. The defendant calculated and intentionally crafted the scheme to ensure that Plaintiff and members of the Class would be over-billed for the drugs. In designing and implementing the 5% Scheme, McKesson was cognizant at all times of the fact that End Payors rely on the integrity of the pharmaceutical companies, wholesalers and publishers in setting the AWP, as reported by the publishers.

206. By intentionally and artificially inflating the AWP by virtue of the increase in the WAC-to-AWP spread, and by subsequently failing to disclose such practices to the individual patients, health plans and their insurers, the defendant engaged in a fraudulent and unlawful course of conduct constituting a pattern of racketeering activity.

207. The co-conspirators' racketeering activities amounted to a common course of conduct, with similar pattern and purpose, intended to deceive Plaintiff and other End Payors. Each separate use of the U.S. mails and/or interstate wire facilities employed by the co-conspirators was related, had similar intended purposes, involved similar participants and methods of execution, and had the same results affecting the same victims, including Plaintiff. McKesson and First Data have each engaged in the pattern of racketeering activity for the purpose of conducting the ongoing business affairs of its particular McKesson-First Data Enterprise.

E. The State Relied on the Accuracy of the Falsely Inflated AWP Published by First Data and/or MediSpan

208. In implementing its fraudulent scheme, defendant was acutely aware that Plaintiff and other End Payors relied on the AWP published by First Data and MediSpan as a pricing benchmark.

209. The AWP-based reimbursement benchmark for payments in the retail class of pharmaceutical trade has long been acknowledged. The two largest public purchaser programs for prescription pharmaceuticals – Medicaid and Medicare – historically relied upon published average wholesale prices as the fundamental basis upon which to reimburse for branded drug ingredient costs incurred by dispensers (retail pharmacies for Medicaid, and medical providers in the Medicare arena). Those paying for drugs, by statute or contract rely on and use the published AWP.

210. At all times relevant to this lawsuit First Data and McKesson knew that governmental and public payors such as the State of Connecticut utilize AWP as a pricing benchmark. McKesson was not only aware that First Data was the premier industry source for AWP information but also that First Data supplied its pricing information to Medi-Span, thus, as McKesson acknowledged, “[t]his means that Medispan data is the First DataBank data.” McKesson engaged in a fraudulent scheme with First Data, knowing that First Data was in the best position to cause industry-wide changes to the AWPs and that First Data’s purported method of calculating AWPs would both appear to legitimize the increases and keep McKesson’s pivotal role in the scheme a secret.

211. Once McKesson and First Data raised the WAC-to-AWP spread to 25% on a given drug that spread remained in place and still remains in place to this day and thus continues to injure those entities – including the State of Connecticut – that rely on AWP as a pricing standard.

F. Damages Caused by McKesson’s Five Percent Spread Scheme

212. The State of Connecticut has been injured in its business and property by reason of these violations in that it has made millions of dollars in overpayments that it would not have made had defendant not engaged in its pattern of racketeering activity. McKesson and First

DataBank's violations of federal law and their pattern of racketeering activity have directly and proximately injured Plaintiff because it has paid many millions of dollars in inflated reimbursements or other payments for drugs whose AWP was artificially raised as described herein.

213. McKesson and its co-conspirator, First Data, sent AWP information through the U.S. mails or by interstate wire facilities and reported AWPs and other information by the same methods in furtherance of their 5% Scheme. Plaintiff has made inflated payments for drugs based on and/or in reliance on reported and false AWPs.

214. Under the provisions of Section 1964(c) of RICO, McKesson is jointly and severally liable to Plaintiff for three times the damages that Plaintiff has sustained, plus the costs of bringing this suit, including reasonable attorneys' fees.

SECOND COUNT

SECTION 1 OF THE SHERMAN ACT (15 U.S.C. § 1)

215. Plaintiff incorporates by reference all preceding paragraphs as if fully set forth herein and further alleges as follows.

216. The combination or conspiracy alleged in this Complaint consisted of a continuing agreement, understanding or concert of action by McKesson, along with its co-conspirator, First DataBank, the substantial terms of which were to raise, fix and maintain the AWPs of brand-name drugs at 25% over WAC, and raised prices in the market for brand-name drugs. The effected market is the market for brand-name drugs.

217. McKesson had the power to set retail prices in the market for brand-name prescription drugs. McKesson acted with an illicit purpose of raising prices to create goodwill

with its retail pharmacy customers and did in fact cause harm to consumer and competition as a result.

218. In the ordinary, non-monopoly case, companies do not have the ability to set interbrand prices for an entire product market unless they enter into an agreement with other producers. But the prescription drug industry is defined by profound market imperfections that enabled McKesson to set retail prices of all brand drugs at FDB without collaboration of either its competitors (*i.e.*, national wholesalers, AmeriSource Bergen and Cardinal) or its suppliers.

These features include:

Industry-wide reliance on AWP's to set retail prices of brand drugs;

Industry-wide reliance on First DataBank to calculate and disseminate AWP's;

First DataBank's secretive survey process to calculate AWP's;

Pre-scheme stability of and industry-wide reliance on established manufacturer markups;

First DataBank's power to set prices;

McKesson's role and market power as a major wholesaler; and

AmeriSource Bergen and Cardinal's private refusal to participate in the survey process.

As a practical matter, the distinction between this case, involving an agreement between McKesson and FDB to set retail prices and the hypothetical collusion of wholesalers to accomplish the same result is a distinction without a difference.

219. The fact that McKesson and FDB are not competitors in the rivalrous sense does not take away from the fact that they shared "a conscious commitment to a common scheme designed to achieve an unlawful objective." *Monsanto Co. v. Spray-Rite Serv. Corp.*, 465 U.S. 752, 764 (1984).

220. The price-fixing conspiracy was intended to affect directly the End Payors of the Marked Up Drugs, *i.e.*, Plaintiff and other End Payors. The intent, purpose and effect of the conspiracy was to cause over-reimbursement for these drugs, and thereby increase retail pharmacy profit margins on the sales of the Marked Up Drugs to the detriment of End Payors, including the State.

221. McKesson's scheme had a profoundly anticompetitive effect and no pro-competitive effect. McKesson obtained an unfair advantage in its competition with other wholesalers for retail pharmacies' business. Because it did not have to compete fairly, McKesson believed it could offer fewer incentives to its customers than in an unrestrained market.¹¹ By the same token, manufacturers have an interest in the efficient distribution of their products. McKesson disrupted this process by unilaterally changing the price structure of hundreds of brand drugs, thereby subjecting manufacturers to potential lost sales and/or market share. The effect of the price fix was to disrupt the "central nervous system" of the market for brand-name drugs. And of course Plaintiff and other End Payors were injured because they were forced to pay higher prices without any benefit in terms of better products or better service.

222. Through the price-fixing conspiracy, defendant has in fact caused an increase in reimbursement or payments for the Marked Up Drugs and at the same time the conspiracy had the intent, purpose and effect of increasing profits for all other participants in the distribution chain (*i.e.*, pharmacies and/or PBMs in their retail capacity) as well as for McKesson and FDB.

223. As a result of defendant's wrongful conduct, Plaintiff paid higher prices for the Marked Up Drugs than it would have paid but for defendant's anticompetitive conduct, has been

¹¹ *See, e.g.*, MCKAWP 0065895 (Bob James e-mail discussing how McKesson could avoid giving year end deals to one of its customers if it explained how McKesson's price fixing had benefited the customer, and relating James' discussions with other customers about its price fixing activities: "In my discussions, one of the comments that was made was 'this would certainly be a good reason to renew our agreement with McKesson when its time.' Talk about being good partners, wow!").

injured in its business or property, and has suffered damages in an amount to be determined at trial.

224. Plaintiff and other End Payors in Connecticut are directly harmed by defendant's agreement to raise and fix AWP/WAC markups in that they are the first and only ones in the distribution chain that actually pay the overcharge. The harm that Plaintiff incurred is not the result of a pass-on or otherwise derivative of any harm suffered by an upstream seller. On the contrary, retail pharmacies (including PBMs' mail order pharmacy businesses), from whom Plaintiff purchased the drugs *directly benefited* from the increased markups in the form of higher profit margins on the sales of Marked Up Drugs.

225. Plaintiff is entitled to recover all damages and treble damages allowed under 15 U.S.C. § 15 against McKesson together with their costs of suit, including reasonable attorneys' fees.

THIRD COUNT

USE OF DECEPTIVE TRADE PRACTICES IN VIOLATION OF THE CONNECTICUT UNFAIR TRADE PRACTICES ACT (CONN. GEN. STAT. § 42-110a, *et seq.*)

226. The State realleges and incorporates herein by reference each of the allegations contained in the preceding paragraphs of this Complaint.

227. Defendant's course of conduct, as alleged herein, has been undertaken in the conduct of trade or commerce, as defined in Conn. Gen. Stat. § 42-110a(4).

228. Defendant systematically and continually conducts business throughout the State of Connecticut in that it markets, advertises and sells the drugs that are the subject of this lawsuit.

229. In the course of trade or commerce, including the selling and distribution of pharmaceutical products to its retail pharmacy customers in Connecticut, the defendant

McKesson made, directly or indirectly, explicitly or by implication, representations of the AWP's of brand prescription drugs to First DataBank, knowing that its representations would be published both by First DataBank and MediSpan.

230. In truth and in fact, the AWP's provided to these reporting services were false in that they were based on inflated AWP/WAC markups as part of McKesson's Five Percent Scheme.

231. As a direct result of McKesson's misrepresentations, CMAP and Connecticut consumers have been injured by having to pay excessive amounts for brand prescription drugs based on AWP's marked up by McKesson's Five Percent Scheme.

232. McKesson's misrepresentations, as alleged herein, have been and are material, false and likely to mislead and, therefore, constitute deceptive acts or practices in violation of Conn. Gen. Stat. § 42-110b(a).

233. By doing the aforesaid acts or practices, defendant has engaged in unfair or deceptive acts or practices in violation of Conn. Gen. Stat. § 42-110b(a) and the State seeks damages and restitution.

FOURTH COUNT

WILLFUL USE OF DECEPTIVE TRADE PRACTICES IN VIOLATION OF CONNECTICUT UNFAIR TRADE PRACTICES ACT (CONN. GEN. STAT. § 42-110a, *et seq.*)

234. Plaintiff incorporates by reference all preceding paragraphs as if fully set forth herein and further alleges as follows.

235. McKesson has violated Conn. Gen. Stat. § 42-110b(a) willfully in that it knew or should have known that its conduct was a violation of § 42-110b.

FIFTH COUNT

**USE OF UNFAIR TRADE PRACTICES IN VIOLATION OF
CONNECTICUT UNFAIR TRADE PRACTICES ACT
(CONN. GEN. STAT. § 42-110a, *et seq.*)**

236. Plaintiff incorporates by reference all preceding paragraphs as if fully set forth herein and further alleges as follows.

237. Defendant's course of conduct was and is immoral, unethical, oppressive, unscrupulous, and caused and continues to cause substantial injury to the State of Connecticut and Connecticut consumers.

238. Defendant's course of wrongful conduct, as alleged herein, violates the public policy of the State of Connecticut as pleaded above, as follows:

- (a) The public policy against unlawful price fixing as set forth in the preceding paragraphs, as embodied in 15 U.S.C. § 1;
- (b) The public policy against engaging in racketeering or racketeering conspiracy, as embodied in 18 U.S.C. § 1962(c) & 18 U.S.C. § 1962(d);
- (c) The public policy of reimbursing for drugs at AWP minus a specified percentage, as embodied in Conn. Gen. Stat. §§ 17b-280, 17b-490, *et seq.* and Regulations of Connecticut State Agencies §§ 17-134d-81b, 17b-262-448(q), and 17b-262-611(b)(4), 17b-262-684, *et seq.*; and
- (d) The public policy which prohibits the offering or the payment of cash or a benefit to influence the purchase of goods or services for which reimbursement is claimed from a state or federal agency, as embodied in Conn. Gen. Stat. § 53a-161d

239. As a direct result of defendant's deceptive, unfair, unconscionable, and fraudulent conduct, the CMAP and Connecticut consumers have been injured by paying substantial funds that they would not have paid for but for defendant's unfair and deceptive conduct.

240. Defendant's misrepresentations, acts and practices, as alleged herein, constitute unfair acts or practices in violation of Conn. Gen. Stat. § 42-110b(a).

241. By doing the aforesaid acts or practices, the defendants has engaged in unfair acts or practices in violation of Conn. Gen. Stat. § 42-110b(a).

SIXTH COUNT

**WILLFUL USE OF UNFAIR TRADE PRACTICES IN VIOLATION
OF CONNECTICUT UNFAIR TRADE PRACTICES ACT
(CONN. GEN. STAT. § 42-110a, *et seq.*)**

242. Plaintiff incorporates by reference all preceding paragraphs as if fully set forth herein and further alleges as follows.

243. Defendants violated Conn. Gen. Stat. § 42-110b(a) willfully in that they knew or should have known that its conduct was a violation of § 42-110b.

PRAYER FOR RELIEF


WHEREFORE, Plaintiff prays for judgment and relief against McKesson as follows:

- A. On Plaintiff's RICO claim, as outlined in Count One: three times the damages Plaintiff has sustained as a result of defendant's conduct, such amount to be determined at trial, plus Plaintiff's costs in this suit, including reasonable attorneys' fee;
- B. On Plaintiff's antitrust claim as outlined in Count Two: three times the damages Plaintiff has sustained as a result of defendant's conduct, such amount to be determined at trial, plus Plaintiff's costs in this suit, including reasonable attorneys' fee;
- C. On Plaintiff's Connecticut Unfair Trade Practices Act claims, as outlined in Counts Three through Six, restitution to the State of Connecticut and injured consumers, injunctive and equitable relief as appropriate, and civil penalties for each willful violation of the Act, plus Plaintiff's costs in this suit, including reasonable attorney's fees;
- D. Awarding Plaintiffs Interest as provided by law; and
- E. Such other legal or equitable relief as the Court may deem appropriate.


DATED: May 28, 2008

Respectfully submitted,


STATE OF CONNECTICUT



RICHARD BLUMENTHAL
ATTORNEY GENERAL




Robert B. Teitelman
Assistant Attorney General



Thomas J. Saadi
Assistant Attorney General

Office of the Attorney General
55 Elm Street, P.O. Box 120
Hartford, CT 06141-0120
Telephone: (860) 808-5355
Facsimile: (860) 808-5391
robert.teitelman@po.state.ct.us
thomas.saadi@po.state.ct.us

By 

Thomas Sobol (BBO #471770)
Edward Notargiacomo (BBO #567636)
Hagens Berman Sobol Shapiro LLP
One Main Street, 4th Floor
Cambridge, MA 02142
Telephone: (617) 482-3700
Facsimile: (617) 482-3003

Steve W. Berman
Sean R. Matt
Nick Styant-Browne
Barbara A. Mahoney
Hagens Berman Sobol Shapiro LLP
1301 Fifth Avenue, Suite 2900
Seattle, WA 98101
Telephone: (206) 623-7292
Facsimile: (206) 623-0594